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Ocular angiogenesis, or the formation of new blood vessels in the eye, is the leading 
cause of blindness in a variety of clinical conditions.  Success in elucidation of 
several key steps in angiogenesis cascade has opened a door for anti-angiogenesis 
therapies.  Development of novel therapeutic agents provides effective treatment for 
ocular disorders.  However, treatment of many posterior segment diseases like age-
related macular degeneration (AMD) and diabetic retinopathy (DRP) is far from 
satisfactory due to the limited availability of novel therapeutic drugs and the low 
efficiency of traditional drug delivery methods.  In the present study, we investigated 
the anti-angiogenic properties of a novel small integrin antagonist, EMD478761, and 
developed sustained release systems to locally and continuously deliver this 
compound.   
  
In part I, sustained delivery implants were designed and investigation of their 
anti-angiogenic efficacy, including inhibition and regression, was performed using in 
vivo chick chorioallantoic membrane (CAM) assay.  In part II, laser-induced 
choroidal neovascularization (CNV) rat model was employed to further examine the 
angiogenic inhibitory effect of EMD478761 from a sustained release microimplant.  
And in part III, the pharmacodynamics of EMD478761 was studied to reveal the 
mechanisms by which EMD478761 inhibited angiogenesis.  
Results from in vivo CAM assay and CNV rat model demonstrated that 
EMD478761 inhibited and regressed basic fibroblast growth factor (bFGF)-induced 
angiogenesis, and suppressed laser-induced CNV via sustained release implants.  The 
pharmacodynamics of this drug was studied to better understand the mechanisms of 
the drug’s action mode in preventing neovascularization.  In vitro, EMD478761 
inhibited human umbilical vein endothelial cell (HUVEC) proliferation, caused 
HUVEC detachment in vitronectin-coated surfaces in a time- and dose-dependent 
manner, and disrupted endothelial cell tube formation on Matrigel.  In addition, 
EMD478761 induced HUVEC apoptosis on vitronectin via caspase-3 activation 
pathway.  In vivo, EMD478761 induced endothelial cell apoptosis within CNV 
lesions as demonstrated by terminal deoxynucleotidyl transferase dUTP nick-end 
labeling (TUNEL) assay.  In addition, EMD478761 increased the integrin αvβ3 
internalization in HUVECs, while it did not affect integrin αvβ3 expression levels after 
12 hours treatment.  Taken together, these findings demonstrate that sustained 
delivery of EMD478761 may provide an effective antiangiogenic approach for the 
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Chapter 1:  Introduction 
 
 
1.1  Background and Motivations 
 
1.1.1  Ocular Angiogenesis 
Angiogenesis-related ocular diseases such as age-related macular degeneration (AMD) 
and diabetic retinopathy (DRP) are the leading cause of legal blindness in the developed 
countries (1, 2).  Retinal neovascularization often occurs in young people with DPR.  
Choroidal neovascularization (CNV), as seen in AMD, mainly affects aged individuals.  
Around 9 million US citizens are suffering from AMD and the number of people affected 
by AMD is expected to double by 2020, according to estimates by the Foundation Fight 
Blindness (3).  The threat of a rapidly aging population provides the impetus for 
aggressive efforts to control the prevalence and progression of this disease.  
There are two forms of AMD (Fig. 1-1): the dry form, characterized by drusen 
formation and photoreceptor degeneration, and the wet form (exudative form), 
characterized by choroidal neovascularization and fluid accumulation under the retina 
(4).  Dry form AMD accounts for 90% of cases, and it progresses slowly.  However, there 
is no efficient treatment available yet.  CNV only accounts for 10% of the patients 





Figure 1-1.  Fundus photograph of patients with age-related macular degeneration (AMD). 
(http://nei.nih.gov, http://dermatlas.jhmi.edu)  A) Dry form AMD with drusen deposition; 
B) Schematic diagram of dry form AMD; C) Wet (Neovascular) AMD; D) Schematic 
diagram of wet form AMD  
 
 
Moreover, patients with dry form are often at the risk of developing into wet form.  
Although significant progress has been made in identifying factors that promote or inhibit 
angiogenesis, current treatments for CNV, including laser panretinal photocoagulation 




Visudyne® as a photodynamic therapy, and macular translocation, are not optimal for 
majority of the affected individuals (5-7).  Patients under these treatments often suffer 
significant recurrence. 
The importance of ocular angiogenesis has stimulated the search for novel 
therapeutic agents and efficient delivery methods that either directly target the new vessel 
formation or potentially facilitate the prevention of neovascularization.  The roles of anti-
angiogenic agents are important when considering therapeutic strategies for neovascular 
diseases.  These agents can affect various aspects of the angiogenic process, including 
endothelial cell migration and proliferation, and the three-dimensional restructuring of 
blood vessels.  Our understanding of the molecular events involved in the angiogenic 
process has advanced significantly since the purification of the first angiogenic molecules 
nearly two decades ago (8).  These advances have led to the development of several 
compounds that are currently approved for the treatment of ocular angiogenesis, others 
that are in various phases of clinical trials, and several factors with promising pre-clinical 
data that suggest their potential therapeutic use as anti-angiogenic compounds or targets.  
Among those compounds, the anti- vascular endothelial growth factor (VEGF) drugs 
represent a breakthrough in ocular pharmaceuticals.  Nevertheless, they are often large, 
complex molecules that are difficult to pass through the ocular barriers, and are routinely 
delivered by the invasive intravitreal administration.  
Given the short half life of most drugs injected into the vitreous (9, 10) and the 
recurrence of neovascularization, repeated intravitreal injections may be required to 
maintain drug concentrations within their therapeutic windows.  However, multiple 




associated with cataract formation, retinal detachment and endophthalmitis (11-13).  To 
improve the treatment for CNV, other alternative therapeutic modalities including novel 
antiangiogenic compounds and delivery methods need to be explored. 
A better understanding of the mechanism of CNV will provide a basis for 
alternative treatments.  CNV is the result of pathological angiogenesis which is a 
multistage, complex process involving a series of biochemical signals and receptors 
working together to create the “angiogenesis cascade” (Fig. 1-2).  This process is 
delicately regulated and balanced by angiogenesis activators and inhibitors in the normal 
adult.  However, it may be turned on by specific angiogenic molecules, such as basic and 
acidic fibroblast growth factor (FGF) (14), VEGF (15), transforming growth factor (16). 
tumor necrosis factor α (17), and platelet derived growth factor (18, 19).  The central 
mechanism of angiogenesis requires proteolysis of the extracellular matrix, proliferation, 
migration of endothelial cells, and synthesis of new matrix components.  Once the 
endothelial tube is formed from the existing vasculature, maturation starts with 
recruitment of mural cell precursors and formation of a new basement membrane. 
During angiogenesis, endothelial cells response to the extracellular matrix (ECM) 
is partially mediated by integrins, a superfamily of transmembrane glycoprotein receptors 
that participate in cell-to-cell and cell-to-substrate interactions (20).  In ocular 
angiogenesis, some integrins, growth factors, and proteinases have been found up-
regulated (13, 21-26), which results in endothelial cell activation, proliferation and 
migration.  Thus far, VEGF and proteolytic enzymes such as matrix metalloproteinases 
(MMPs) have become the primary treatment targets (27-30).  A number of studies have 





Figure 1-2.  Angiogenesis cascade. 
(http://www.angio.org/understanding/understanding.html). (1) Angiogenic growth factors 
released from diseased or injured tissues, (2) binding to their receptors on endothelial 
cells, (3) activating signal transduction pathways and (4) stimulating endothelial 
proliferation, (5) migration, and (6) vessel formation.  (7) Bone marrow derived 
endothelial stem cells are mobilized and become incorporated into new blood vessels.  (8) 
Stabilization of the vasculature occurs through the recruitment of smooth muscle cells 






administration of VEGF-neutralizing antibodies, the use of soluble VEGF receptor 
chimeric proteins or VEGF receptor suppressing small interfering RNA (siRNA), and the 
inhibition of VEGF signaling using specific kinase inhibitors (31-34).  However, only 
two anti-VEGF therapies, MacugenTM (pegaptanib sodium) and LucentisTM 
(ranibizumab), have been approved by the FDA for the treatment of advanced AMD at 
this point.  A third anti-VEGF therapy, AvastinTM (bevacizumab), a humanized full-
length antibody against VEGF formulated as an intravenous drug, has been approved for 
treating colorectal cancer, but not specifically for ophthalmic use.  However, AvastinTM 
has been widely used off-label to treat advanced CNV (35-38).  Despite all the 
excitement that these agents have generated, the long-term effects of any of these anti-
VEGF agents are still unclear (39).   
On the other hand, targeting VEGF might be problematic as a therapy for ocular 
neovascularization.  VEGF is a multifunctional factor that is constitutively produced by 
the retinal pigmented epithelium (RPE) of the normal eye.  One of the functions of VEGF 
is to serve as a survival factor for retinal vessels (40).  In addition, the chronic nature of 
CNV and the intrinsic risk of repeated intraocular injections might necessitate a 
prolonged systemic administration of VEGF antagonists, which could adversely affect 
other ocular tissues or organ systems.  Accordingly, there continues to be an unmet 
medical need to search for new and safe therapeutic agents and novel delivery methods. 
Alternative drugs that block other key components of angiogenesis cascade have 
been developed.  Some of these compounds, such as anecortave acetate, pigment 
epithelium-derived factor (PEDF) and µPA/µPAR inhibitor Å6, have entered clinical 




cortisol acetate that decreases extracellular protease expression and inhibits endothelial 
cell migration (41), was administrated through posterior juxtascleral injection with a 
specially designed cannula after a small incision was made in the conjunctiva and 
Tenon’s capsule.  Six and twelve months after treatment, the visual acuity of those 
patients with 15 mg anecortave acetate injection was better than the placebo (42, 43).  In 
addition, this dose of the drug prevented severe vision loss without causing clinical side 
effects.  PEDF, which is present in the corneal and the vitreous, has been found to be the 
most potent natural inhibitor in cell migration assay.  PEDF has been in clinical trial 
using an adenoviral gene delivery system (GeneVec) for patients with severe CNV, who 
are not eligible for laser or PDT treatment (44).  Å6, an inhibitor of the 
urokinase/urokinase receptor, is in phase I clinical trial, and its safety and tolerability is 
being investigated in CNV patients (Angstron Pharmaceiticals) (45).  Despite all the 
progress that has been made, all of these treatments, while successful in halting vision 
deterioration in the majority of patients, are only effective in improving vision in 6-33% 
of patients (46-49).  To improve the treatment for CNV, alternative therapeutic modalities 
including novel antiangiogenic compounds and delivery methods are being explored. 
Although the exact cause of CNV is poorly understood, increasing evidence has 
shown that angiogenesis is partially regulated by integrin molecules (24, 25), a 
superfamily of transmembrane glycoprotein receptors that are involved in signal 
transductions (20).  Integrins are heterodimeric cell adhesion molecules consisting of 
noncovalently associated α and β subunits.  The α subunit is relatively long, consisting of 
around 1000-1200 amino acids and some contain an insert domain (I domain) near the 




Integrins are not only the main receptors for ECM proteins, such as fibronectin 
vitronectin , collagens and laminin (50),  but also provide anchor points for the 
cytoskeleton and mediate signaling events through a complex of associated adaptor 
proteins and kinases (51).  To date, 24 integrins, with different combinations of the α and 
β chains, have been reported in mammalian cells (Fig. 1-3) (52).  
Integrin-mediated signaling events are crucial for cell proliferation, migration, 
survival and differentiation (53).  Integrins signaling can be directly activated by ligand 
binding, or indirectly stimulated by growth factors or cytokines.  Depending on the 
composition of the ECM, integrins can activate one or more intra-cellular signaling 
pathways.  This is called “outside-in signaling”, which typically involves phosphorylation 
of focal adhesion kinase (FAK), recruitment of adaptor proteins, activation of small 
GTPases and subsequent activation of downstream effector molecules (54).   On the other 
hand, integrins also respond to intracellular cues and alter the way in which they interact 
with the ECM.  This is so called “inside-out signaling”, which regulates integrin 
adhesiveness by modulating the affinity and avidity of integrins to their ECM ligands, 
therefore controlling cell adhesion, migration and proliferation (54) .  Many studies 
indicate that integrins are important modulators of postnatal angiogenesis (55).  Integrin 
αvβ3 is highly expressed in angiogenic endothelial cells in wound granulation tissue and 
in malignant tumors (24, 56).  In ocular angiogenesis, αvβ3 has been found selectively 
expressed on the CNV membrane, while both of αvβ3 and αvβ5 are present in diabetic 
retinopathy tissue (25).  The fact that anti- αvβ3 antibodies and some other integrin 






Figure 1-3.  Integrin heterodimers and their subfamilies (52).  The integrin family can be 
classified into the following subfamilies: the RGD-binding integrins (blue), the I-domain 
containing integrins (green), the laminin-binding integrins (red), the leukocyte integrins 
(black) and the α4-subfamily integrins (purple). 
 
 
angiogenesis in several animal models (24, 25, 57, 58), suggests that αvβ3 and αvβ5 might 
be good targets for ocular angiogenesis treatment.  Most of these integrin antagonists are 
peptides that are delivered by either systemic administration or intravitreal injection.  
Repeated ocular drug applications are often required to achieve efficacy while frequently 
cause discomfort to the patient and side effects in other tissues.  In this study, we selected 




αvβ3/αvβ5 and investigated its anti-angiogenic properties from a sustained delivery 
implant. 
 
1.1.2  Eye Anatomy and Ocular Barriers 
The eye is a very delicate sense organ and presents several anatomic and physiologic 
barriers that pose a major challenge for ocular drug delivery (Fig. 1-4).  It has three 
layers: the outer fibrous layer of connective tissue forms the cornea and sclera, the middle 
vascular layer is composed of iris, ciliary body and choroid, and the inner nervous layer 
is the retina.  These layers form three compartments: anterior chamber, posterior chamber 
and vitreous chamber.  Among the eye structures are three intraocular fluids: aqueous 
humor, vitreous humor and blood.  
Clinically, the eye can be considered to be composed of an anterior segment and a 
posterior segment and each segment forms its unique barriers.  In the anterior segment, 
the cornea and lens are highly resistant to drug penetration.  The cornea is a nonvascular 
optically transparent tissue.  The central part of the cornea is about 0.5 mm thick and it is 
composed of 5 layers: epithelium and its basement membrane, Bowman’s layer, stroma, 
Descemet’s membrane and endothelium.  The epithelium is a hydrophobic layer with 
many tight junctions which impede drug penetration into the eye.  Bowman’s layer lies 
between the epithelium and the stroma, the major tissue of the cornea.  In contrast to the 
epithelium, the stroma is highly hydrophilic consisting of 85% of water.  The 
endothelium layer contacts with the aqueous humor.  It is the unique structure of the 




Indeed, less than 5% of drug can penetrate into the vitreous through topical eye drop 
application (59). 
The posterior segment of the eye consists of three layers, the sclera, choroid, and 
retina that surround the vitreous cavity.  The sclera is a tough opaque fibrous layer, 
mainly composed of water and connective tissue.  The choroid is a highly vascular and 
pigmented tissue that lines the inner surface of the sclera.  It carries the largest blood flow 
per unit tissue in the body, brings in the nutrients for the outer layers of the retina and 
absorbs energy as light strikes the retinal pigment epithelium (60).  The retina is a multi-
cellular membrane occupying the internal space of the posterior portion of the eyeball.  
The retina is composed of neural retina and retinal pigment epithelium (RPE).  The 
detailed retinal structure is shown in Figure 1-4C.  The inner border of neural retina faces 
vitreous and the outer border is next to RPE.  Neural retina is composed of nine layers 
whereas RPE is a monolayer of polarized cells.  Bruch’s membrane provides a basal 
lamina for the RPE cells, and it is located between RPE and choroid capillaris.  The blood 
supply to the inner two thirds of the retina comes from the retinal vessels.  The choroidal 
circulation nourishes the outer one third of the neural retina and RPE.  The retinal 
endothelial cells have basal lamina that are surrounded by pericytes.  The blood–retinal 
barrier (BRB), which has been shown to have similar features to the blood–brain barrier, 
restricts the movements of substances following systemic and periocular administration 
to the retina.  The blood–retinal barrier is composed of two parts: the outer part is formed 
by RPE and the inner part by the endothelial cells of the retinal vessels.  In the RPE and 




the permeation barrier to hydrophilic substances, thereby limiting the transfer of 
compounds both to inward (blood to vitreous) and outward (vitreous to blood) directions. 
The blood ocular barriers, consisting of the blood-aqueous and blood-retinal 
barriers, are the main obstacles for the effective treatment of most intraocular diseases by 
systemic drug delivery (61).  The blood-aqueous barrier is composed of ciliary non-
pigmented epithelium and iridal vascular endothelium. This barrier limits the access of 
hydrophilic drugs from plasma into the aqueous humor (61, 62).  The inner and outer 
blood-retinal barriers are formed by retinal pigment epithelium and retinal vascular 
endothelium, respectively.  The inner limiting membrane on the vitreoretinal interface 
imposes a formidable barrier to macromolecules such as antibodies. 
In summary, the eye represents many barriers that hinder drug delivery into the 
back of the eye.  Efficient drug delivery systems for posterior segment ocular diseases 
need to overcome those barriers to achieve therapeutic drug concentrations while 





Figure 1-4.  Human eye anatomy and main barriers to ocular drug delivery.  A) Human 
eye anatomy; B) Schematic illustration of choroidal vasculature; C) Structure of the 
retina (http://thalamus.wustl.edu/course/eyeret.html).  RPE: retinal pigment epithelium; 
ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: 
inner plexiform layer; GCL: ganglion cell layer; OFL: optic fiber layer; ILM: inner 
limiting membrane.  The main barriers are cornea, sclera, ILM, RPE, blood-aqueous and 




1.1.3  Ocular Drug Delivery Methods 
The unique anatomy of the eye allows not only for systemic ophthalmic drug delivery, 
but also local, topical and very targeted drug delivery.  As mentioned before, systemic 
administration is subject to blood-aqueous and blood-retinal barriers.  Thus, repeated 
drug application and high dosage are often required for refractory vitreoretinal diseases 
such as choroidal neovascularization.  Other principal methods of ocular therapeutic 
agent delivery, including topical eye drops, intravitreal or suprascleral injection, and 
controlled release implants (scleral plug, intravitreal implant, subconjunctival implant, 
transscleral implant and suprachoroidal implant) (Fig.1-5) (63), have been investigated to 
tackle the sight-threatening diseases.  Among those, topical ophthalmic drops are the 
most common formulations used.  However, it has been found that less than 5% of 
applied drug reaches the intraocular tissue because of the formidable cornea and scleral 
barriers and the continuous turnover of tears (59). 
Intraocular injection through pars plana has been widely used in the clinic to 
deliver high concentration of drugs to the posterior tissues.  However, drugs injected 
inside the vitreous are often rapidly cleared by the aqueous humor, the fast choroidal 
blood flow, or by enzymatic degradation.  Consequently, frequent treatments are often 
necessary to maintain drug concentrations within therapeutic windows.  
An ideal pharmaceutical approach for patients with ocular angiogenesis would be 
to incorporate a system that maintains the therapeutic drug levels in the targeted disease 















Sustained delivery devices may offer an excellent alternative to multiple 
intravitreous injections.  These controlled release devices can deliver drugs at predictable 
and constant release rates for an extended period of time, thus avoiding the frequency of 
repeated injections.  Microsphere and nanoparticle formulations have gained popularity 
in the past few decades for controlled drug delivery, especially for proteins and peptides.  
One of the main advantages of these particle formulations is to provide stability for labile 
compounds that are often rapidly degraded or cleared out in vivo. Macrophages or 
enzymes such as proteases in the surrounding tissues would not be in contact with the 
encapsulated drug until it is released from the matrix.  Moreover, microspheres or 
nanoparticles are readily injected intravitreally, subcutaneously or into other target sites 
without surgery.  Microparticles diffuse poorly in the vitreous gel, thus act like reservoir 
after intravitreal injection.  Poly (lactic acid) (PLA) microspheres remain in the vitreous 
of the normal rabbit eye for as long as 1.5 months (64).  In contrast, nanoparticles diffuse 
rapidly and can be easily internalized into ocular tissues and cells (65, 66).  The residence 
time of these particles depends not only on their sizes, but also on the physiological 
conditions of the eyes where the particles are injected.  For example, the clearance of 
liposomes from vitreous in infected eyes is found to be much faster than those in the 
normal eye.  This might be a result of increase rate of diffusion through the liquified 
vitreous, or an elevated uptake by recruited macrophages, or by a breakdown of the 
blood-retinal barrier in infected eyes (67).  However, PLA or poly (lactic-co-glycolic) 
acid (PLGA) containing particles have been found to induce inflammatory reactions in 
the eye (66).  Nevertheless, albumin nanoparticles have shown excellent intraocular 




Despite of the advantages that these micro-or nanoparticles offer, delivery of a 
large amount of drug for an extended period of time is still challenging.  To overcome 
this problem, several implants have been developed and investigated.  Drugs are usually 
encapsulated (reservoir implant) (70) or blended (matrix implant) (71) within a particular 
matrix, or conjugated to polymer carriers (72).  The advantage of these implants is that 
release rates are determined by the matrix employed and the properties of the drugs 
incorporated.  The release rates can be typically controlled well below toxic levels, and at 
the same time, higher drug concentrations can be intraocularly delivered without causing 
systemic side effects.  According to the properties of the polymer used, these devices are 
either biostable (e.g. silicone) or biodegradable (e.g. PLA, PLGA, poly vinyl alcohol 
(PVA), liposome, gelatin, albumin etc).  For posterior segment diseases, an intravitreal 
implant is often used to avoid the major ocular barriers.  Cylindrical PLGA implant 
loaded with 1 mg fluorouracil allowed drug release for nearly 3 weeks in vitreous cavity 
of rabbits and reduced the incidence of tractional retinal detachment (73).  However, the 
implant itself caused trauma to the retina.  Vitrasert™ (Bausch and Lomb, Rochester, 
NY) is one of the first FDA approved reservoir type implants for the treatment of 
cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency.  It is 
capable of releasing drug for about 8 months with in vivo release rates between 0.5 and 
2.88 µg/h and has been shown to be therapeutically effective in human CMV retinitis 
(74).  Other implants that have been developed include scleral plugs and rod-shaped 





In summary, various ocular implants have been engineered to avoid or minimize 
the ocular barriers that often impede the delivery of drug via traditional methods. 
 
1.2  Objectives and Approaches 
The research objective of this dissertation was to develop a sustained delivery system for 
a small integrin antagonist, EMD478761, and to determine its efficacy via a sustained 
delivery method for preventing and/or reversing ocular angiogenesis, and finally, to 
investigate the mechanisms under which this compound acts.   
To this end, we explored the integration of a potential therapeutic compound with 
sustained release systems as a route to provide a useful modality for CNV treatment. We 
focused on systems where the drug targets a specific angiogenesis marker and the carriers 
allow for a continuous long time release of this drug to the posterior segment of the eye.    
The following studies have been done: 
 1.  Reservoir type sustained delivery implants releasing EMD478761 have been 
designed.  In vitro release rates of these implants were measured, and parameters 
influencing their release rates were evaluated and optimized. 
 2.  The effect of EMD478761 on angiogenesis inhibition or regression using in 
vitro and in vivo angiogenesis assays has been studied, and the differences between bolus 
dosing and sustained implant delivery methods were compared. 
 3.  The mechanisms of the drug’s effect on angiogenesis inhibition have been 
investigated.  In particular, integrin expression, internalization and endothelial cell 




1.3  Significance  
The studies described in this dissertation are potentially significant from several different 
standpoints: (a) they offer a feasible therapeutic approach for fast growing ocular 
angiogenesis management by expanding the availability of therapeutic agents and 
prolonging the delivery time period; (b) they provide fundamental insight into the action 
model of this drug that could be important for the development and utilization of a new 





Chapter 2:  In vivo Angiogenesis Inhibition in Chick 
Chorioallantoic Membrane (CAM) Assay from a Sustained 
Release EMD478761 Implant 
 
 
Part of results in this chapter was published in the following journal article: 
Y. Fu, M. L. Ponce, M. Thill, P. Yuan, N.S. Wang and K.G. Csaky. 2007. Angiogenesis 
Inhibition and Choroidal Neovascularization Suppression by Sustained Delivery of an 
Integrin Antagonist EMD478761. Invest Ophthalmol Vis Sci 48(11):5184-5190 
 
2.1  Purpose 
Most studies of angiogenesis inducers and inhibitors rely on various in vitro and in vivo 
models as indicators of efficacy.  In this chapter, we have designed sustained release 
implants for a small molecular integrin antagonist, EMD478761, and we employ a 
modified in vivo chick chorioallantoic membrane (CAM) assay to investigate the anti-
angiogenic efficacy of EMD478761 from sustained release implants. 
 
2.2  Introduction 
The field of angiogenesis has become active since neovascularization has been found to 




choroidal neovascularization and diabetic retinopathy (78).  The molecular basis is being 
studied in many branches of biology. Angiogenesis is a multi-stage, complex process that 
involves an appropriate environment of growth factors, extracellular matrix proteins, 
proteases, as well as cell surface integrins to be present so that cellular events of 
proliferation, proteolysis, invasion and migration can take place (79).  Identification and 
assessment of new substances with the ability to inhibit angiogenesis highly relies on in 
vitro and in vivo assays. The chick chorioallantoic membrane (CAM) assay is frequently 
used for anti-angiogenic drug screening, due to its advantages of economy, high capacity 
and ease of manipulation (80, 81). 
The chorioallantoic membrane (Fig. 2-1)  is an extraembryonic membrane which 
serves as a gas exchange surface and its respiratory function is provided by an extensive 
capillary network (82).  Its development starts at embryonal day 4 and the chorionic and 
the allantoic epithelia together with the vascularized stroma participate in its formation. 
Undifferentiated blood vessels, scattered in the mesoderm, grow very rapidly until day 8, 
forming a network of capillaries that migrate to occupy an area at the base of the chorion 
and mediate gas exchange with the outer environment. Rapid capillary proliferation goes 
on until day 10; thereafter, the endothelial mitotic index declines rapidly, and the vascular 
system attains its final arrangement on day 18, just before hatching.  Because of its 
extensive vascularization, the CAM has been utilized as an in vivo model for the 
evaluation of angiogenic and anti-angiogenic molecules.  
The development of the vascular system of the CAM is a complex, highly 
regulated process that depends on genetic and epigenetic factors expressed by endothelial 




angiogenic in the CAM assay (57), we used basic fibroblast growth factor (bFGF) as an 
angiogenic stimulus to investigate the anti-angiogenesis efficacy of EMD478761 from a 














2.3  Materials and Methods 
 
2.3.1  Implant Design 
Circular EMD478761 containing reservoir implants were designed (Fig. 2-2) using the 
following procedure: a 10%-20% (w/v) polyvinyl alcohol (PVA) solution was formulated 
by placing 3-6 g of PVA (Airvol® 125) in 30 ml of molecular biology grade water 
(Eppendorf Scientific, Inc, Westbury, NY) in a closed vial, and placed in a water bath at 
100°C until completely dissolved.  The freshly made PVA solution was poured onto a 
glass plate forming a thin film. Compressed pellets, containing either 2mg (1.5 mm), 4 
mg (2 mm) or 10 mg (4 mm) of EMD478761 were embedded within this film during its 
wet phase.  After allowing the film to dry at room temperature, sections of the film with 
the drug core centered within the section were cut with a biopsy puncher (Acu Punch® 2 
mm, 2.5 mm or 4.5 mm, Acuderm, USA).  Each section represented a reservoir implant.  
 The PVA polymer used this study is made by complete hydrolysis of polyvinyl 
acetate to remove acetate groups, rather than by polymerization of the corresponding 
vinyl alcohol monomer.  At room temperature, its solubility is very low (~ 4%), 
therefore, it is necessary to heat and stir to make PVA solutions. Once PVA film is 
formed, it is pretty stable within a long period of time at physiological temperature. 
To determine the influence of formulation parameters on release rates of the 
implants, the implants were made with different matrix concentrations, compressed pellet 




no drug was incorporated. All implants were sterilized (3 x 10 4 grays, gamma radiation) 
before use.  
 
2.3.2  In Vitro Release Rates 
In vitro release rates on representative implants of each design were measured daily with 
an HPLC.  Five implants from each design were randomly selected and placed in a closed 
vial with a constant volume of phosphate buffered saline (PBS, pH 7.4) at 37°C.  PBS 
was replaced every 24 hours.  The drug assays were performed with an Agilent HP1100 
HPLC system (Agilent Technologies, Palo Alto, CA) equipped with a G1329A 
autosampler, a G1315A diode array detector, a G1312A binary pump, and a Dell 
workstation that controlled the operation of HPLC and analyzed the data.  A Beckman 
Ultrasphere C-18 column (5 µm; 4.6 × 250 mm) (Beckman Coulter, Inc., Fullerton, CA) 
was used for separation, and detection was set at 280 nm. The flow rate used was 1.0 
mL/min with a mobile phase of 20% of acetonitrile, 40% of water, and 40% of methanol 
by volume. The retention time was 5.0 minutes, and the detection limit was 10 ng/mL. 
The release rates were determined by calculating the amount of drug released in a given 
volume over time and recorded for each implant design in µg/day (± 1 standard deviation 
(SD)).  The cumulative drug released was calculated based on daily release rates and 








Figure 2-2.  Representative image of circular implants. The 2-mm diameter implants 
made with 15% PVA were shown. Sham implant was made without EMD478761. 
 
 
2.3.3  CAM 
The CAM assay was performed using 10-day-old embryonated eggs (CBT, Charlestown, 
MD) as described previously with slight modification (83).  A doughnut glass coverslip 
was constructed by creating a 2.5 mm hole in an 8 mm glass coverslip.  On embryonal 
day 3, 3 ml of ovalbumin was removed from each egg.  After opening windows on 




doughnut glass coverslips, was applied to the CAM.  Implant A was placed centrally in 
the pre-cut circular hole in the coverslip to locally deliver the drug. The eggs were 
photographed 3 days after the stimulus was added and the angiogenesis response was 
examined.  The neovascularization area was quantified with a modular imaging software 
(Openlab, ver 3.1.5, Improvision Inc., Lexington, MA). 
 To determine the ability of sustained delivery of EMD478761 to regress 
neovascularization, an EMD478761 implant with 2 mm diameter and 15% PVA was 
added to the pre-cut circular hole in the coverslip 3 days after bFGF applied to the CAM.  
Neovascularization responses were examined 2 or 4 days after implantation and the 










2.4  Results 
 
2.4.1  In vitro Release Rates of EMD478761 Implant 
To optimize the release rates of the implants, we investigated the parameters that may 
influence the release kinetics of the implants, including PVA concentration, implant size, 
curing temperature and initial drug encapsulation amount. 
Figure 2-4 shows the in vitro release profiles of various circular implants with 
diameter sizes of 2.0, 2.5 and 4.5 mm.  The initial mean drug loading amounts are 2, 4 
and 10 mg, respectively.  As shown in Figure 2-4A, the circular implants delivered an 
initial bolus of drug on the first day followed by a steady-state release of drug throughout 
the assay period.  The size of the implants greatly influenced in vitro mean release rate.  
Over the assay period, the mean release rates of the implants increased with the increase 
of the implant sizes.  The steady-state cumulative release after day 1, estimated from the 
mean release rates, followed a zero order release kinetics (Fig 2-4), which is typical for 
diffusion controlled reservoir implants (84).  The steady-state release rate for 2.0 mm 
implant was 119 ± 30 µg/day.  By day 17, drug was completely released from 2.0 mm 
implant, while about 91.2% and 80.9% of drug was released from 2.5 and 4.5 mm 
implant, respectively.   
We next examined the effect of curing temperature on in vitro release rates of the 
implants.  For this experiment, the 2.0 mm implants were further incubated at 110°C or 
150 °C for 3 hours.  Figure 2-5A demonstrates that the in vitro release rate of the 





Figure 2-4.  In vitro mean release rates (A) and cumulative release amount (B) of circular 
implants (n=5) with different diameters at 37°C. The implants were made with 15% 
PVA.  Initial average drug loading amounts were 10, 4 and 2 mg for 4.5, 2.5 and 2 mm 





Figure 2-5.  Effect of curing temperature on in vitro release rates (A) and cumulative 
release amount (B) of the implants (n=5).  Implants were 2.0 mm in diameter and were 
made with 15% PVA. RT: room temperature; 110-3hrs: heated at 110°C for 3 hours; 150-




5B, the mean cumulative release amount by day 4 decreased 20.5% and 39.3% for 
implants heated at 110°C and 150°C, respectively, as compared to controls.  The effect of 
PVA concentrations on in vitro release rates was also investigated with 2.0 mm implants.  
As shown in Figure 2-6, the in vitro release rates of EMD478761 implants were inversely 
proportional to the concentrations of PVA. 
These results suggest that the release rates of EMD478761 reservoir implants can 
be finely tuned, by adjusting the size of the implant, the curing temperature or the PVA 
concentration, to deliver constant drug levels over a long period of time.  In the following 
in vivo CAM assay, a doughnut glass coverslip with a 2.5 mm hole was constructed.  
Therefore, a 2.0 mm EMD478761 implant was used.  The implant was made with 15% 
PVA at room temperature. 
 
2.4.2  Sustained Delivery of EMD478761 Inhibits Angiogenesis in the CAM 
To evaluate the inhibitory effect of EMD478761 implant on blocking bFGF-induced 
angiogenesis in an in vivo animal model, we used a modified CAM assay.  To induce 
angiogenesis, a modified doughnut shaped coverslip with a 2.5 mm hole at its center was 
constructed.  The angiogenesis stimulus, bFGF, was dried on the coverslip and placed on 
the CAM.  An EMD478761 implant or sham was placed at the center of the doughnut 
glass coverslip.  Results showed that the EMD478761 implant (Fig. 2-7C) significantly 
inhibited bFGF-induced neovascularization, relative to controls (Fig. 2-7), by 93%.  No 





Figure 2-6.  Effect of PVA concentrations on in vitro release rates (A) and cumulative 





controls (Fig. 2-7A).  The mean neovascularization area induced by bFGF alone was 6.8 
mm2 (Fig. 2-8B) and the neovascular response was 83% positive (Fig. 2-8A).  Vehicle 
(sham) treated CAMs did not have an effect on inhibiting bFGF-induced vessel formation 
and followed a similar response in which the neovascularization area was unchanged.  On 
the other hand, in the presence of EMD478761 implant, only 19% of the bFGF-induced 
CAMs were weakly angiogenic, and the angiogenesis area was dramatically reduced to 
an average of 0.47 mm2, which is significantly different from those treated with bFGF 
only (P = 0.0008) or with sham (P = 0.0001).  In addition, there were no signs of local 
drug toxicity and no effect on the normal CAM vasculature was observed (Fig. 2-7B, C).  
 
2.4.3  EMD478761 Implant Reverses Angiogenesis in the CAM 
Since we observed the significant inhibitory effect of sustained delivery of EMD478761 
on an in vivo CAM assay, we decided to examine whether EMD478761 delivered by this 
method could reverse angiogenesis, a process which is more relevant to 
neovascularization-related diseases, using the same model system.  To this end, 
angiogenesis on the CAM was induced by bFGF on 10-day old embryos and 
EMD478761 implant was placed 3 days after bFGF was applied.  CAMs were examined 
2 or 4 days after implantation.  Figure 2-9 showed that bFGF-induced angiogenesis was 
remarkably abrogated 2 days after EMD478761 implant treatment.  The mean 
neovascularization area decreased from 6.7 mm2 to 1.3 mm2 (Fig. 2-10, P < 0.001), yet no 





Figure 2-7.  Effect of EMD478761 implant on angiogenesis inhibition in the chick CAM 
assay.  A). bFGF only; B). bFGF with sham placed at the center of the coverslip; C). 
bFGF with an EMD478761 implant.  The right panels are the corresponding magnified 
images showing the neovasculature. Arrows indicate the position of the implant used per 








Figure 2-8.  Quantitative analysis of angiogenesis response to bFGF, sham and EMD 
implant in the chick CAM assay in terms of percent of positive CAMs (A) and 






Continuous treatment for 2 more days did not further affect the neovascularization area 
(Fig. 2-10).  In addition, no apparent signs of local drug toxicity were noted and the 
normal CAM vasculature appeared to be unaffected.  These findings suggest that 
sustained delivery of EMD478761 may be effective in treating angiogenesis-related 
diseases. 
 
2.5  Discussion 
Angiogenesis plays a vital role in normal physiological development, such as wound 
healing, embryogenesis, and many diseases including solid tumors and ocular 
neovascularizations.  Previous studies demonstrated that continuous delivery of 
endostatin by an osmotic pump increased its potency and efficacy on tumor therapies (9). 
In this study, we designed sustained release implants to locally and continuously deliver 
EMD478761.  As expected, the release rates of the implants were governed by their size, 
matrix concentration, and curing temperature.  
Quiescent normal vessels do not express detectable levels of integrin αvβ3, 
however, bFGF stimulates the specific expression of the integrin αvβ3 on angiogenic 
blood vessels in CAM (25, 85).  Since EMD478761 is an αvβ3 integrin antagonist, we 
first examined the inhibitory effect of EMD478761 on bFGF-induced angiogenesis in a 
modified CAM model.  Differing from previous CAM assays where the testing 
compounds are often added exogenously to the angiogenesis stimuli (25, 83), we used a 
sustained release implant to continuously and locally deliver the drug.  Sustained delivery 





Figure 2-9.  Effect of EMD implant on bFGF induced angiogenesis regression.   
A). Right after implantation; B). 2 days after EMD implant treatment; C, D). Magnified 







Figure 2-10.  Effect of EMD478761 on bFGF-induced angiogenesis regression from the 
sustained release implant.  Histograms show mean neovascular area ± SD after treatment 




normal CAM vessels, suggesting that the drug acts as an angiogenic antagonist.  This 
antagonistic effect could be the result of EMD478761 interacting and/or binding to the 
αvβ3 integrin expressed on cell membrane of sprouting CAM vessels.  Moreover, 
sustained-delivery of EMD478761 dramatically reversed bFGF-induced angiogenesis in 
the CAM.  As endothelial cells are implant players for neovascularization, regression of 




subsequent programmed endothelial cell death.  On the other hand, the over-expressed 
integrin αvβ3 on bFGF-induced neovasculature may be preferentially occupied by 
EMD478761, due to the high binding affinity of EMD478761 to integrin αvβ3, leading to 
the disruption of integrin-mediated endothelial cell survival signals.  In addition, integrins 
are constantly produced and recycled between cell plasma and intracellular 
compartments. Sustained delivery of EMD478761 may continuously bind to the 
unoccupied integrin receptors that recycled back to the plasma, therefore constantly 
suppresses many cellular events involving integrin signaling.  The data presented here not 
only showed that sustained delivery of EMD478761 has an anti-angiogenesis effect on 
the CAM, but also that this effect is restricted to proliferating vessels rather than 
mature/quiescent vasculature, indicating that EMD478761 holds a high selectivity as 
anti-angiogenic agent.  The potent suppression of bFGF-induced angiogenesis 
demonstrated the activity of this integrin antagonist and its potential applications to CNV. 
It should be noted that the CAM assay has its own limitations as it relates to the 
interpretation of the angiogenic response.  The main limitation is the nonspecific 
inflammatory reactions that may develop as a result of implantation, addition of 
angiogenic stimuli, or potential contamination.  The inflammatory reaction often impedes 
the quantification of angiogenesis responses to treatments, making vessel counting 
impossible.  Other limitations include possible false increase of vessel density due to the 
rearrangement of existing vessels that follow contraction of the membrane, and time for 
inducing angiogenesis.  Many developmental studies show that by embryonic day 10, 
CAM is fully developed, while its final arrangement continues until by embryonic day 




has already stopped.  In this study, we quantified the angiogenic response by measuring 
the neovascularization area instead of angiogenesis index (57, 83) or vascular numbers 
(86)  
Previous experiments using CAM and rabbit corneal models demonstrated that 
there are at least 2 distinct integrin-dependent angiogenesis pathways: 1) one induced by 
basic fibroblast growth factor (bFGF) and tissue necrosis factor α (TNF- α), and mediated 
by integrin αvβ3; 2) the other mediated by integrin αvβ5 and induced by vascular 
endothelial growth factor (VEGF), transforming growth factor α (TGF- α) or the phorbol 
ester phorbo 12-myristate 13-acetate (PMA) (25).  The data presented in this study 
suggest that integrin-dependent angiogenesis pathways may be suppressed by specific 
integrin antagonists. 
 
2.6  Conclusions 
Sustained delivery of EMD478761 by a PVA reservoir implant significantly 
inhibits bFGF-induced angiogenesis in the CAM and it can also regress 
neovascularization.  In addition, mature CAM vasculatures are not affected possibly due 
to the absence of integrins αvβ3 and αvβ5.  These results suggest that integrin antagonists 





Chapter 3:  Experimental Choroidal Neovascularization 
Suppression in Rats from EMD478761 Microimplant  
 
 
Part of the results of this chapter was published in the following journal article: 
Y. Fu, M. L. Ponce, M. Thill, P. Yuan, N.S. Wang and K.G. Csaky. 2007. Angiogenesis 
Inhibition and Choroidal Neovascularization Suppression by Sustained Delivery of an 
Integrin Antagonist EMD478761. Invest Ophthalmol Vis Sci. 48(11): 5184-90. 
 
3.1  Purpose 
Initial studies on the CAM assay suggest that EMD478761 can suppress cytokine-
induced angiogenesis.  The results from this screening experiment motivate the more 
relevant animal studies to investigate if EMD478761 can inhibit choroidal 
neovascularization in a rat model from a sustained release microimplant. 
 
3.2  Introduction 
Choroidal neovascularization is the primary cause of severe vision loss in retinal 
diseases.  In the presence of CNV, the barrier function of Bruch’s membrane is 
compromised.  CNV can develop within the subretinal space between the RPE and the 
photoreceptor outer segment or under the RPE.  Several therapeutic strategies have been 




efficient CNV suppression is not only dependent on novel therapeutic drugs, but also on 
the appropriate delivery method.  Due to the protective barriers encountered in the eye 
and to the short half-lives of the majority drugs inside the vitreous, a long-release 
formulation of drug delivery could be more appropriate for the treatment of CNV.  In this 
study, we have designed a sustained release microimplant and investigated its effect on 
CNV inhibition in rats. 
The inhibitory effect of EMD478761 on experimental CNV was studied with a 
well validated laser trauma rat model.  In this model, laser photocoagulation selectively 
ablates the photoreceptor outer segments, RPE, choroicapillaris, and portions of the 
anterior choroid.  The subsequent wound response includes the in-growth of fibroblasts, 
RPE, and vascular endothelial cells that form a defined neovascular lesion (90).  In 
addition, this particular animal laser model does not exhibit the rapid spontaneous 
regression of the neovascular process.  Therefore, this is a suitable and well-accepted 
model to study the effect of sustained delivery of EMD478761 on angiogenesis inhibition 
and/or regression of CNV. 
 
3.3  Materials and Methods 
 
3.3.1  Microimplant Design and in vitro Release Rates 
EMD containing microimplants were designed (Fig. 3-1) in a similar fashion to the 
circular implant using the following procedures: a polyvinyl alcohol (PVA) 




(Airvol® 125) in 30 ml of molecular biology grade water in a closed vial, and placed in a 
water bath at 100°C until completely dissolved.  Several PVA concentrations were 
formulated ranging from 10% to 20%.  The freshly made PVA solution was poured onto 
a glass plate forming a thin film. Compressed pellets, containing about 250 µg of 
EMD478761 were embedded within this film during its wet phase. After allowing the 
film to dry at room temperature, sections of the film with the drug core centered within 
the section were cut with a razor blade.  Each section represented a reservoir 
microimplant measuring 1x1x2 mm.  Sham implants were made in a similar fashion 
except that no drug was incorporated. All implants were sterilized (3 x 10 4 grays, gamma 
radiation) before use.  
In vitro release rates on representative implants of each design were measured 
daily with an HPLC.  Each implant was placed in a vial with a constant volume of 
phosphate buffered saline (PBS) (pH 7.4) at 37° C.  The PBS was replaced every 24 
hours to simulate sink conditions.  HPLC detection parameters were set as previously 
described in chapter 2.  The release rates were determined by calculating the amount of 
drug released in a given volume over time and recorded for each implant design in 
µg/day (± 1 SD).  The cumulative drug released was calculated by integrating the area 







Figure 3-1.  Representative image of microimplant made from 15% PVA.  Sham implant 
contains no drug.  The final dimension of the microimplant is 1 x 1 x 2 mm. 
 
 
3.3.1  Animals and CNV Induction 
All procedures were performed with strict adherence to guidelines for animal care and 
experimentation prepared by the Association for Research in Vision and Ophthalmology, 
and by the National Eye Institute/National Institutes of Health.  Male adult (250 g) 
Brown-Norway rats (Charles River Laboratories, Raleigh, NC) were used to evaluate the 
effect of intravitreal EMD478761 microimplants versus control implants on laser-induced 




ketamine at 70 mg/kg and xylazine at 30 mg/kg.  After receiving anesthesia, the pupils of 
the rats were dilated with 1% tropicamide ophthalmic solution (Mydriacyl®, Alcon, Fort 
Worth, TX).  The fundus was visualized with a slit lamp biomicroscope (Haag-Streit, 
Mason, OH) using a slide coverslip as a contact lens.  A diode red laser (810 nm; Iris 
Medical Instruments, Inc., Mountain View, CA) was used to induce CNV by rupturing 
the Bruch’s membrane.  Laser parameters were set to 75 µm spot size, 100 ms exposure, 
and 150 mW power.  A series of four laser lesions were placed at approximately equal 
distance around the optic discs of both eyes of the animals.  Eyes that bled or showed no 
bubble formation were excluded. 
 
3.3.3  Intravitreal Injections 
To examine whether bolus injection of EMD478761 is sufficient to abrogate the 
development of CNV, single intravitreal injection of 10 µl of 0.5 mg/ml EMD478761 
was performed through a 32 gauge delivery needle (Hamilton Co., Reno, NV) under a 
Zeiss operating microscope (Thornwood, NY) on 5 animals immediately after laser 
photocoagulation.  For control studies, rats with rupture of Bruch’s membrane in each 
eye were given intravitreally 10 µl of PBS or no injection.  
 
3.3.4  Intravitreal Implantation 
In the current study, an EMD microimplant or a sham implant was placed in the vitreous 




dissected and a small single incision was made with a 20 gauge needle in the superior 
globe, just posterior and parallel to the ora serrata, allowing the microimplant to be 
inserted within the vitreous.  The posterior segment was evaluated immediately after 
insertion to confirm proper placement of the microimplant into the vitreous cavity.  All 
eyes were treated with topical antibiotic ointment (Fougera®, E.Fourera & Co, Melville, 
NY). 
 
3.3.5  CNV Quantification using FITC-dextran Perfusion 
CNV was labeled by vascular perfusion with high molecular weight fluorescein 
isothiocyanate (FITC)-dextran (MW = 1x 106) by a similar method previously described 
(90, 91).  The rats were sacrificed with 100% CO2 2 weeks after laser photocoagulation 
and perfused with 5 ml of PBS, 5 ml of 4% (w/v) paraformaldehyde (PFA) and 5 ml of 
10mg/ml high molecular weight FITC-dextran (Sigma, St. Louis, MO).  Eyes were 
immediately enucleated and fixed in 4% PFA.  Choroidal flatmounts were made, as 
previous described (90, 91), by hemisecting the eye and removing of the retina.  CNV 
from implant treatment, intravitreal injection and laser controls was thereafter examined 
by a fluorescence microscope (Olympus BX50, Melville, NY).  Images of the 
neovascular lesions were captured with a CCD color video camera (Retiga EX, Burnaby, 
BC, Canada) coupled to a Macintosh computer.  Areas of CNV were measured with 












3.3.6  Histopathological Studies 
Five eyes from each treatment group were collected 2 weeks after laser photocoagulation 
for histologic studies.  Treated CNV lesions were compared with the control lesions, 
which had been induced with the same pattern of laser injury.  After euthanasia, rat eyes 
were immediately collected, placed in plastic molds filled with embedding medium 
(Tissue-Tek O.C.T. Compound, Sakura Finetek, Torrance, CA) and flash frozen on dry 
ice.  Frozen eyes were sectioned transversely on a cryostat at -20˚C at 10-µm thick. 
Ocular frozen sections were air dried and fixed with freshly prepared 4% PFA in PBS at 
room temperature for 15 minutes and rinsed with PBS three times.  The prepared sections 
were then stained with hematoxylin and eosin. 
Further studies on CNV lesions were performed using vibrating microtome 
sections.  After euthanized, the eyes were enucleated and fixed in 4% PFA for 4 hours 
and then the eyes were cleaned and hemisected to remove the anterior segment.  The 
posterior segment of the eye was embedded in 7% (w/v) agarose type XI (Sigma, St. 
Louis, MO), and sectioned with a vibrating microtome (Leica, VT-S1000, Bannockburn,  
IL) at 100 µm thickness. The vibration frequency was set to 3 Hz.  Ocular sections were 
blocked with 5% normal goat serum in I.C.C. buffer (0.5% bovine serum albumin, 0.2% 
Tween-20, 0.05% sodium azide, PBS, pH 7.3) at 4°C for 4 hours.  Sections were 
incubated with Alexa Fluor 488-conjugated isolectin IB4 (1:50, Invitrogen, Carlsbad, 
CA) and 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI, 1:1000, Invitrogen) in 
2% normal goat serum in I.C.C buffer overnight at 4°C.  Sections were then washed three 





(Biomedia Corp., Foster City, CA).  Images were taken with a confocal microscope (SP2: 
Leica, Exton, PA). 
 
3.3.7  Statistical Analysis 
All data are presented as the mean ± SD.  The data were statistically evaluated by 
student’s t-test.  P ≤ 0.05 is considered statistically significant. 
 
3.4  Results 
 
3.4.1  In vitro Release Rates of the Implants 
Microimplants made with different concentrations of PVA demonstrated a similar release 
profile: deliver an initial burst of drug on the first day, followed by a constant release rate 
for the next 10 days, which then gradually decreased over time (Fig. 3-3).  Moreover, the 
release rates of the implants were inversely related to their PVA concentrations.  Implants 
made with higher PVA concentrations showed slower release rates as expected.  In 
addition, the steady-state mean release rates between days 2 and 11 remained constant, 
typical for a diffusion controlled reservoir implant (84).  The steady-state release rate of 
the implants made with 15% PVA was 18.5 ± 3.8 µg/day.  Those made with 10% and 
20% PVA had steady-state release rates of 28.5 ± 9.6 µg/day and 13.4 ± 3.2 µg/day, 
respectively.  These results indicate that the microimplants can slowly release drug for 





Figure 3-3.  Mean release rates of the microimplants made with 10%, 15% and 20% PVA. 
 
 
3.4.2  Effect of Intravitreal Injection of EMD478761 on Laser-Induced CNV 
Laser photocoagulation of the RPE-choroid resulting in reproducible experimental CNV 
has been well validated by several groups (90, 92-94).  To examine whether bolus 
administration of EMD478761 can lead to significant suppression of the development of 
laser-induced CNV, a single intravitreal injection of EMD478761 at the dose of 5 µg was 
performed on 5 animals immediately after laser injury.  14 days after treatment, the area 




EMD478761 appeared to be smaller than that of PBS control (Fig. 3-4).  However, the 
differences (12%) between them were not statistically significant (P = 0.68).  This 
suggests that single intravitreous injection in rats at the maximal allowable soluble dose 
is not able to maintain levels of EMD478761 sufficient to significantly inhibit CNV. 
 
3.4.3  Effect of EMD478761 Microimplant on Laser-Induced CNV 
To explore the feasibility of local and sustained delivery of EMD478761 microimplants 
to inhibit laser-induced CNV in rats, we placed an EMD microimplant or sham implant 
into the vitreous cavity of the right eye after the laser-induction was performed.  Left eyes 
served as laser controls.  Five animals from each treatment were sacrificed 14 days after 
implantation.  EMD microimplants inhibited CNV relative to sham implant and laser 
controls in a statistically significant fashion (P < 0.05).  14 days after laser induction, in 
the eyes that received EMD478761 microimplant, the mean CNV areas of the lesions 
decreased 65% and 63%, respectively, as compared to those of laser controls and sham 
implant treated eyes (Fig. 3-5, 3-6).  In addition, there was no significant difference 








Figure 3-4.  Effect of intravitreal injection of EMD48761 on laser-induced CNV.  A) 
CNV control with intravitreal PBS injection; B) Intravitreal EMD478761 treated CNV. 
The vasculature was labeled with FITC-dextran 2 weeks after laser photocoagulation. 






Figure 3-5.  Effect of EMD478761 microimplant on laser-induced CNV. A) Laser control 
lesion; B) Sham implant treated CNV; C) EMD478761 microimplant treated CNV.  Scale 






Figure 3-6.  Quantitative CNV areas measured from lesions 2 weeks after laser treatment 
(* P< 0.05 compared to laser control and sham).  The vasculature was labeled via cardiac 
perfusion 2 weeks after laser photocoagulation. 
 
 
3.4.4  Histological Studies 
Two weeks after CNV induction, histopathology of eyes treated with laser or PBS 
revealed numerous new blood vessels arising from the disrupted RPE and Bruch’s 
membrane (Fig. 3-7A and B).  Eyes treated with intravitreal bolus injection of 
EMD478761 demonstrated a similar response to those treated with PBS (Fig. 3-7C).  In 




membranes and few new blood vessels under the retina (Fig. 3-7E).  Sham implant 
treated eyes showed a similar response to those of laser controls (Fig. 3-7A, D), 
indicating that there was no inhibitory effect of the sham implant on CNV.  These results 
are consistent with those of CNV areas calculated from choroidal flatmounts.  
Examination of the slides showed an absence of inflammatory cells in both EMD 
implants and sham implants. 
 Results from immunohistochemical staining with isolectin IB4 (Fig. 3-8), which 
selectively stains vascular cells and allows visualization of CNV, corroborates the above 
findings.  Control eyes (Fig. 3-8A, C) demonstrated extensive new vessel formation 
under the retina.  Intravitreal injection of EMD478761 failed to inhibit CNV, while 
sustained delivery of EMD478761 using a microimplant almost completely suppressed 










Figure 3-7.  Hematoxylin-eosin stained light microscopy images of CNV 2 weeks after 
laser photocoagulation. Each image shows the center of CNV lesions.  Minimum of 10 
lesions per treatment was examined. (A-E) Histologic sections of the eye with laser 
control, intravitreal PBS injection, intravitreal EMD 478761 injection, sham implant And 






Figure 3-8.  Immunohistochemical staining of CNV lesions in rats.  Vibrotome sections 
of CNV (14d) were stained for vascular cells with isolectin IB4 (green) and nuclei were 
counterstained with DAPI (blue).  Each image shows the center of the lesion.  A) CNV 
cross section of control eye; B) CNV lesion from an intravitreal EMD478761 treated eye;  
C) Sham implant treated CNV lesion; D) CNV from an eye treated for 14 days with an 




3.5  Discussion 
CNV posses a great vision threat to the senior population world wide.  Conventional 
treatments have demonstrated limited success in improving or preserving the visual 
function of CNV affected patients.  The roles of anti-angiogenic agents are important in 
that these agents can affect various aspects of the angiogenic cascade, including 
endothelial cell migration and proliferation, and neovasculature formation.  Although 
numerous antiangiogenic compounds such as triamcinolone acetonide, TNP-470 and 
some monoclonal antibodies , have been used to target choroidal neovascularization (33, 
58, 72, 93, 95-97), results are far from satisfactory.  Currently there are only two anti-
VEGF therapies, MacugenTM (pegaptanib sodium, Eyetech, Inc.) and LucentisTM 
(ranibizumab, Genetech, Inc.), that have been approved by the FDA for the treatment of 
advanced AMD.  However, the majority of these drugs are delivered via intravitreal 
injections (33, 93, 97, 98).  Given the formidable ocular drug delivery barriers and the 
short half-lives of drugs inside the vitreous, maintaining therapeutically efficacious levels 
of drug may be achieved either by continuous or repeated injections, or by a mechanism 
whereby the drug is sustained released by an implanted device.  Although the laser-
induced model is controversial as to whether it mimics the most common form of 
naturally occurring CNV, in age-related macular degeneration, its essential process 
resembles that of CNV, including breaking of Bruch’s membrane, vascular endothelial 
cell migration and proliferation, and tube formation. Moreover, this model does not 
exhibit the rapid spontaneous regression of the neovascular process which makes it useful 
for the evaluation of anti-angiogenic treatments.  In this study, we demonstrated a 




molecule integrin antagonist of αvβ3 and αvβ5, to the site of neovascularization in a laser-
induced rat model.   
Angiogenesis is partially regulated by integrins (24, 25).  The αvβ3 and α5β1 
integrins appear to be over-expressed in laser-induced CNV in rats (88) and mice (26), 
but not on normal choroidal vessels.  The high expression and up-regulation of these 
integrins suggests that they may play an important role in CNV.  Indeed several 
antagonists to these integrins have been developed, and they potently inhibit cytokine- 
and tumor- mediated angiogenesis in different animal models (26, 58, 99-103).  
Intravitreal injection of cyclic RGD, an αv-integrin antagonist, effectively inhibited 
progression of laser-induced CNV in rats (93).  Systemic administration of JSM6427, an 
integrin antagonist to α5β1, significantly suppressed the development of CNV in mice by 
33 to 40% (26).  In this work, we observed that intravitreal bolus injection of 
EMD478761 failed to attenuate the development of CNV.  The low efficacy of this 
delivery route was not surprising as the dosage used in this study, which was limited by 
its aqueous solubility (~500 µg/ml), was 20 times lower than that used for cyclic RGD 
peptides (93).  Other possible explanations for this observation include the quick turnover 
of the integrin αvβ3 receptor (t1/2 < 10 minutes) (104) and rapid elimination of the drug 
from the vitreous (9, 10).  The limited drug solubility, the small vitreous volume, which 
can be estimated at approximately 56 µl (105), as well as the lower levels of drug 
extraction efficiency from ocular tissues (less than 65%, H. Kim, 2007, unpublished data) 
preclude a direct, in vivo pharmacokinetic measurement of EMD478761 in the rat eye.  
However, all of these possibilities could be obviated by the use of a sustained delivery 




with an implant has not been previously studied.  For these reasons, we have designed a 
sustained release delivery system that would provide a therapeutic dose for this 
compound for an extended period of time. 
Sustained release microimplants have been shown to be beneficial in ocular 
delivery of other antiangiogenic compounds in that not only they can bypass the main 
ocular delivery barriers by being directly inserted into the vitreous cavity, but also 
prolong the half-life of the drug.  For example, it has been previously shown that 
sustained-release 2-methoxyestradiol silicone implant was safe in normal rabbits and 
suppressed CNV in rats (70).  In another study, Ciulla et al. demonstrated the potent 
inhibition of laser induced CNV in rats by the sustained release of triamcinolone 
acetonide from matrix type microimplants (71).  However, both of these studies were 
relatively qualitative and focused on the effect of the implants on the thickness of the 
lesions by counterstaining the sections with hematoxylin and eosin.  The present study 
demonstrates that EMD478761 can be delivered intraocularly using a sustained release 
PVA reservoir microimplant.  Animals treated with the EMD478761 microimplant 
exhibited a 63% reduction in the CNV area 2 weeks post implantation compared with 
sham treated animals.  Furthermore, new vessels and thicker neovascularization 
membranes were observed in both untreated and sham treated eyes compared to 
EMD478761 implant treated eyes.  The increased potency seen in the sustained delivery 
approach may be attributed partially to the continuous presence of the drug around the 
neovascularization tissues.  Therefore, the angiogenic integrin receptors might be 
constantly suppressed, leading to significant suppression of the development of CNV.  




CNV lesion site (106), the fact that there was no significant difference between sham 
implant treated eyes and laser controls, indicated that CNV inhibition was not an artifact 
of the PVA polymer, but the result of EMD478761 released from the microimplant.  
Histologic studies performed on those eyes treated in the same manner confirmed this 
finding. 
The mechanism by which EMD478761 exerts its anti-angiogenic effect is likely 
to be similar to that by which other integrin antagonists act.  A predominant characteristic 
of CNV is the excessive growth of new blood vessels from the pre-existing vasculature.  
Endothelial cells play a pivotal role as they form a tube in every blood vessel and are 
actively involved in vascular remodeling during CNV.  Therefore, EMD478761 could 
exert their inhibitory effect through either anti-adhesion of endothelial cells to the 
extracellular matrix (93), induction of apoptosis of endothelial cells (107), or through 
changes in the regulation of integrin expression (108).  Additional studies of the 
mechanisms of the drug’s action mode will be investigated in the late chapters to further 
assess the anti-angiogenic efficacy of EMD478761 via this sustained delivery system. 
 
 
3.6  Conclusions 
In conclusion, sustained release EMD478761 implants suppressed laser-induced CNV in 
rats.  These results provided new evidence that sustained release of EMD478761 may be 




Chapter 4:  A Dual Integrin Antagonist EMD478761 Induces 




4.1  Purpose 
To investigate EMD478761’s action mode on angiogenesis inhibition and on its ability to 
reverse angiogenesis in vivo. 
 
4.2  Introduction 
In chapter 2 and 3, we demonstrated that sustained delivery of EMD478761 inhibited 
bFGF-induced angiogenesis in the CAM assay and suppressed laser-induced choroidal 
neovascularization in rats.  However, as a new compound, its anti-angiogenic 
mechanisms are still unknown.  
 Angiogenesis is a multistage complex physiological and pathological event, 
involving endothelial cell activation, extracellular matrix degradation, cell proliferation, 
migration and tube formation.  Therefore, each stage of the angiogenesis cascade could 
be a potential therapeutic target.  As vascular endothelial cells are the key players in new 




preventing endothelial cell adhesion or proliferation, or by regulating the expression of 
extracellular matrix receptors, or by inducing the apoptosis of endothelial cells.  
In this chapter, we have investigated the action modes of this small molecule, 
EMD478761, both in vitro and in vivo.  Particular attention was paid to the ability of this 
compound to inhibit endothelial cell proliferation, and to induce cell apoptosis on 
different substrates and in a laser-induced CNV rat model.  
Apoptosis, or programmed cell death, is a highly ordered form of cell suicide.  
Apoptosis involves chromatin condensation, DNA fragmentation, and the formation of 
membrane-enclosed apoptotic bodies containing well-preserved organelles (109-112).  
We hypothesize that EMD478761 inhibits angiogenesis by induction of endothelial cell 
apoptosis.  To test this hypothesis in vitro, we studied caspases activation and Annexin V 
staining in HUVECs in the presence or absence of EMD478761; in vivo, we examined 
apoptosis using terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine 
triphosphate (dUTP) nick end labeling (TUNEL) on laser-induced CNV lesions.  
 
4.3  Materials and Methods 
 
4.3.1  Compound 
EMD48761, an inner salt of a diastereomerically pure benzoxazione with dual 
antagonism to integrins αvβ3 and αvβ5, was obtained from Merck KGaA (Darmstadt, 




solubilized to a concentration of 0.5 mg/ml in PBS.  Its retention time determined by 
HPLC was 7 minutes.  
  
4.3.2  Endothelial Cell Culture 
Early passage of human umbilical vein endothelial cells (HUVEC) were obtained from 
Vec Technology Inc. (New Jersey, NY).  Cells were maintained in RPMI 1640 
(Invitrogen, Gaithersburg, MD) supplemented with 20% bovine calf serum (BCS) 
(Hyclone Laboratories, Logan, UT  ), 200 µg/ml endothelial cell growth supplement 
(ECGS) (BD Biosciences, San Jose, CA ), 5 units/ml heparin (Sigma, St. Louis, MO), 
100 units/ml penicillin and 50 µg/ml gentamicin at 37 °C.  For all experiments, cells were 
used between passages 3 and 7. 
 
4.3.3  Endothelial Cell Adhesion Assay 
Adhesion assay was performed on 96-well plate.  Tissue culture 96-well plates were 
incubated either with 100 µl of 5 µg/ml of human fibronectin (Sigma, St. Louis, MO), or 
3 µg/ml of recombinant human vitronectin (Invitrogen, Gaithersburg, MD) overnight at 
4°C.  Coated plates were blocked with 0.5% heat denatured bovine serum albumin (BSA) 
(Sigma) for 1 hour at 37°C and rinsed three times with PBS.  Control wells were blocked 
with BSA without prior coating.  Sub-confluent HUVECs were detached with Versene 
(Invitrogen) and washed with RPMI1640 without phenol red.  Cells were pre-incubated 




37°C on fibronectin-or vitronectin-coated plates. After incubation, unattached cells and 
residual buffer were removed.  Cell adhesion was evaluated by fixing and staining the 
adherent cells with 20% methanol containing 0.2% crystal violet.  The plates were 
extensively rinsed with deionized water and the dye was solubilized with 2% sodium 
dodecyl sulfate (SDS).  Absorption values at 595 nm were determined for each well with 
an ELISA microplate reader (Tecan Safire, Durham, NC). 
 
4.3.4  Endothelial Cell Proliferation Assay 
Cell proliferation was carried out using a XTT proliferation assay kit (Roche, 
Indianapolis, IN).  This assay is based on the cleavage of a yellow tetrazolium salt, XTT, 
to form an orange formazan dye by mitochondrial dehydrogenases in living cells (Fig. 4-
1).  Briefly, sub-confluent HUVECs were detached with trypsin/EDTA and seeded at a 
density of 2 x 104 cells/well in a 96-well plate in the presence or absence of EMD478761 
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peptide.  After 24 hours of incubation, cell proliferation was assayed according to the 
manufacture’s instructions.  Initial number of cells served as control. 
 The effect of EMD47876 on human endothelial cell proliferation was further 
investigated immohistochemically by examining bromodeoxyuridine (BrdU) 
incorporation, the expression of cell cycle regulatory proteins, proliferating cell nuclear 
antigen (PCNA) and p21.  In brief, 8-well tissue culture treated glass chambers (BD 
Biosciences) were coated with 20% bovine calf serum (Hyclone, Logan, Utah) in RPMI 
1640 medium (Invitrogen) for 1 hour at 37 °C.  HUVECs were collected and plated at 3 x 
105cells/well in pre-treated 8-chambers.  After the cells reached subconfluence, the 
medium was replaced with endothelial cell serum free medium (Invitrogen) 
supplemented with 0.1% BSA.  Cells were incubated with 0, 0.02, 0.2 and 0.6 µM EMD 
478761 in the presence (BrdU incorporation) or absence (PCNA and p21 expression) of 
10 µM BrdU (Invitrogen, Eugene, OR) for 24 hours.  Cells were then fixed with 4% PFA 
for 15 min at room temperature and blocked with 5% normal goat serum (Sigma) in I.C.C 
buffer for 1 hour.  Cells which were treated in the presence of BrdU, were incubated with 
Alexa Fluor 660-conjugated anti-BrdU antibody.  For detection of PCNA and p21 
expression, cells were incubated with anti-PCNA or p21Waf1/Cip1 primary antibodies 
(Cell Signaling Technology, Berverly, MA) for 1 hour at 1:200 dilution in I.C.C buffer.  
The antigens were then detected with secondary antibodies conjugated to Texas-red X 
(PCNA) or Alexa 488 (p21).  The slides were mounted with anti-fade gel-mount medium 
(Biomedia Corp., Foster City, CA).  Images were taken with a Leica CRT 5000 





4.3.5  Endothelial Cell Detachment  
Tissue culture 6-well plates were incubated overnight at 4°C with 3ml of 5 µg/ml human 
fibronectin (Sigma, St. Louis, MO) or 3 µg/ml vitronectin (Invitrogen).  The plates were 
then blocked with 0.5% bovine serum albumin (BSA) in PBS.  HUVECs were seeded at 
a density of 2 x 105 cells/well in complete medium and incubated overnight.  Cells were 
starved 30 minutes in human endothelial basal medium containing 0.1% BSA. Different 
amounts of EMD478761 were added to the medium, as specified.  After 12 hours 
treatment, cells were examined and stained with Alexa® Fluor 568-conjugated phalloidin 
(Invitrogen) to visualize the actin fibers. Phase contrast and fluorescence images were 
acquired. 
 
4.3.6  Tube Formation 
Tube-forming assays were performed as previously described with slight modifications 
(83).  HUVECs were grown until sub-confluence and treated with 0-1 µM of 
EMD478761 for 1 hour in serum free medium. Cells were collected and plated onto 48-
well dishes containing Matrigel (100 µl/well) at 24,000 cells/well in RPMI 1640 medium 
containing 10% of BCS.  Tube assays were performed in the presence of 0-1 µM of 
EMD478761 as specified.  Controls included cells incubated with medium only or with 
100 µg/ml C16Y, a peptide known to block tube formation.  After overnight incubation, 
cells were fixed and stained with Diff-Quick fixative (methanol) and solution II (6.25% 




tubes were examined and photographed.  EMD478761 was tested in triplicate, and the 
assay was repeated three times. 
 
4.3.7  In vitro Detection of Endothelial Cell Apoptosis 
The ability of EMD478761 to induce endothelial cell apoptosis was examined in vitro by 
using different substrates.  HUVECs cultured on vitronectin- or fibronectin-coated 6-well 
plates to 80% of confluence were incubated with different concentrations of EMD48761 
as specified, for 12 hours or 24 hours.   
4.3.7.1  Quantification of apoptosis by flow cytometry 
After treatment, both floating and attached HUVECs were collected and washed with 
PBS.  The pellets were subjected to Annexin V/propidium iodide (PI) staining using an 
ApopNexin™ Annexin V FITC apoptosis kit according to the manufacture’s instructions 
(Chemicon, Temecula, CA).  The resulting fluorescence was measured by flow cytometry 
(FACSCalibur, Becton Dickinson), and the percentage of apoptotic cells was calculated 
with Cell Quest software (version 3.1f, Becton Dickinson).  Cell staining with a 
combination of Annexin V and PI reveals either non-apoptotic cells (Annexin V-/PI-), 
early apoptotic cells (Annexin V+/PI-), late stage apoptotic cells (Annexin V+/PI+), or 
necrotic cells (Annexin V-/PI+). 
4.3.7.2  Identification of apoptosis by Western blotting 
Subconfluent HUVECs grown on vitronectin-or fibronectin-coated 6-well plates, were 




attached cells were collected and lysed in RIPA buffer (Pierce, Rockford, IL) containing 
complete protease inhibitors (Roche).  Protein concentrations were determined using the 
BCA assay kit (Pierce).  Equal amounts of total protein were separated under reducing 
conditions by 4-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE).  Separated proteins were then transferred onto nitrocellulose membranes 
(Invitrogen).  Membranes were blotted with 5% non-fat milk in TBST buffer (Tris-
buffered saline, 0.05% Tween-20, pH 7.3) before Western blotting with monoclonal anti-
caspase 3, 8, 9 or anti- glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies 
(Cell Signaling Technology).  Membranes were washed three times 5 min each with 
TBST and then incubated with anti-mouse or anti-rabbit peroxidase secondary antibodies 
for 1 hour.  Immune complex on nitrocellulose membranes were detected by enhanced 
chemiluminescence (Pierce). GAPDH served as loading control. 
 
4.3.8  Identification of Apoptotic Cells in vivo by TUNEL Staining 
In vivo apoptosis study was performed on experimental laser-induced CNV in Norway-
Brown rats.  CNV induction was performed as described in Chapter 3.  2 weeks after 
CNV induction, 10 µl of 0.5 mg/ml EMD478761 solution was intravitreally injected to 
both eyes of the animal.  Control animals received 10 µl of PBS.  Treated eyes were 
enucleated 6, 12, 24 and 48 hours after the injections were performed.  At each time 
point, 5 eyes were used to make the choroidal flatmounts and 5 eyes were embedded in 
agarose gel after removing their anterior segments.  The posterior segments of the eyes 




Apoptosis was detected from choroidal-RPE flatmounts and vibrotome sections using an 
ApopTag® in situ apoptosis detection kit, a TUNEL based DNA fragmentation assay, 
according to the manufacture’s instructions with slight modification (Chemicon).  In 
brief, the flatmounts and vibrotome sections were post-fixed with a solution of ethanol: 
acetic acid (2:1) for 5 min at -20°C.  Samples were washed twice with PBS.  20 µl freshly 
prepared TdT enzyme was applied to each sample and incubated for 3 hours at 37°C in a 
humidified chamber.  The enzymatic labeling was stopped by a stop/wash buffer and 
samples were counterstained with rhodamine–conjugated anti-digoxigenin.  To localize 
apoptotic cells within the lesions, samples were also immunohistochemically stained with 
Alexa® Fluor 488-isolectin IB4 (20 µg/ml, from Griffonia simplicifolia) and DAPI 
(1:1000, 5 µg/ml) overnight at 4°C.  Then samples were mounted in aqueous mounting 
medium and images were taken with a confocal microscope (SP2, Leica, Exton, PA) 
equipped with a 40X (1.25 n.a.) oil immersion objective lens.  The resolution of the 
images collected was 1024 x 1024 pixels. 
 
4.4  Results 
 
4.4.1  Effect of EMD478761 on Endothelial Cell Adhesion 
The functional role of EMD478761 on endothelial cells was first investigated using a cell 
adhesion assay.  ECM proteins, fibronectin and vitronectin, were used to quantify the 
effect of EMD478761 on HUVEC adhesion 1 hour after plating.  As shown in Figure 4-2, 




EMD478761 at all concentrations tested as compared to those on control and vitronectin 
surfaces.  However, HUVEC adhesion to fibronectin-coated surfaces was not 
significantly affected by the presence of EMD478761 (Fig 4-2).  Cell adhesion to control 
and vitronectin surfaces was slightly decreased.  Significant difference was observed for 





Figure 4-2.  Effect of EMD478761 on HUVEC adhesion to fibronectin (FN) - and 
vitronectin (VN)-coated surfaces.  HUVECs were plated onto ECM protein coated 96-
well plates in the presence of different concentrations of EMD478761 for 1 hour.  Results 
are mean ± SD of quadruplicates of 1 representative experiment (* P < 0.05 compared to 




4.4.2  Effect of EMD478761 on Endothelial Cells Proliferation 
EMD478761 inhibited and reversed angiogenesis in vivo as demonstrated in Chapter 2 
and 3, and it affected endothelial cell adhesion to vitronectin.  Since endothelial cell 
proliferation is necessary for the formation of new vessels, we decided to examine the 
role of EMD478761 on endothelial cell proliferation.  To this end, we performed a series 
of proliferation assays on cultured HUVECs using different concentrations of 
EMD478761.  We observed that HUVEC proliferation was inhibited by the presence of 
EMD478761 in a dose-dependent manner as demonstrated by the XTT assay (Fig. 4-3).  
Inhibition followed an exponential response.  Proliferation was completely inhibited at 
500 ng/ml.  Control C16Y anti-angiogenic peptide inhibited by 73.3% at 2000 ng/ml. 
The effect of EMD478761 on endothelial cell proliferation was further 
investigated with immunohistochemistry studies of DNA synthesis and the expression of 
cell cycle regulatory proteins, PCNA and p21.  Results showed that treatment of 
HUVECs with EMD478761 revealed a dose-dependent inhibition of BrdU incorporation, 
as compared to control (Fig. 4-4).  These results demonstrated that EMD478761 inhibited 
DNA synthesis in cultured endothelial cells since the majority of cells treated with 
EMD478761 between 0.2 µM and 0.6 µM did not incorporate BrdU (red nuclei).  In 
parallel, the effect of EMD478761 on PCNA, a protein that is actively expressed during 
the cell cycle, was also examined.  The presence of EMD478761 was observed to 
decrease the expression of PCNA as the dose of the drug increased and its expression was 
not detected at concentrations higher than 0.2 µM (Fig. 4-5).  These results suggest that 
EMD478761 inhibits the cell cycle by a mechanism that suppresses the expression of 





Figure 4-3.  Effect of EMD478761 on endothelia cell proliferation by XTT assay.  
HUVEC proliferation was tested by XTT assay in 96-well plate.  C16Y, a known anti-
angiogenesis peptide was used as positive control at a concentration of 2 µg/ml.  Solid 
triangle (▲) indicates the absorption value with initial number of cells. The experiment 
was repeated three times. Results are mean ± SD 1 representative experiment.  
 
 
that regulates the cell cycle at the G1 phase and is not expressed during cell proliferation.  
Our results showed that p21 was not expressed in untreated proliferating cells (Fig.4-6 
top middle panel).  However, treatment with EMD478761 induced the expression and 







Figure 4-4.  Effect of EMD478761 on endothelial cell proliferation by BrdU 
incorporation.  HUVECs were grown in the presence of EMD478761 and BrdU.  Cells 
were then immunostained with anti-BrdU antibody.  Red: Alexa 660-stained BrdU 














Figure 4-5.  Effect of EMD478761 on PCNA expression in HUVECs.  Cells were 
immunostained with anti-PCNA antibody and counterstained with Texas-red X-






Figure 4-6.  Effect of EMD478761 on regulatory cell cycle protein p21 expression in 
HUVECs.  HUVECs were grown in serum free medium after they reached subconfluence 
and treated with different concentrations of EMD478761, as specified, for 24 hours. Cells 
were stained with primary p21 antibody at 1:100 dilution and counterstained with 





panel).  All of these findings indicate that EMD478761 inhibits endothelial cell 
proliferation in a dose-dependent fashion by inducing p21 expression.  The results of 




Table 1.  BrdU incorporation, PCNA and p21 expression in endothelial cells in the 
presence of EMD478761. 
 Control 0.02 µM 0.2 µM 0.6 µM 
BrdU incorporation 65.2 ± 2.2% 36.4 ± 13.9% 17.5 ± 5.6% 18.5 ± 12% 
P value  0.089 0.0078 0.032 
PCNA expression 100% 75.8 ± 1.1% 36.8 ± 13.4% 10.9 ± 0.3% 
P value  0.00096 0.022 0.000005 
p21 expression 0% 17.0 ± 3.2% 31.1 ± 11.6% 26.3 ± 0.1% 
P value  0.0018 0.013 0.000002 
Note: Data were shown in percentages of positive stained endothelial cells ± SD for 3 







4.4.3  Effect of EMD478761 on Endothelial Cell Detachment on Vitronectin 
We examined the ability of EMD478761 to detach adherent cells from their substrates.  
Endothelial cell adhesion to ECM protein is integrin dependent.  The attachment of 
endothelial cells to vitronectin is dependent on the engagement of αvβ3 and αvβ5 integrins 
and on their localization in functional cell-matrix adhesions (113).  For these 
experiments, HUVECs were allowed to grow to confluence on vitronectin coated 6-well 
plates or on 8-well chamber slides.  Cells were then treated with different concentrations 
of EMD478761 for 24 hours.  Cell morphology was monitored by phase contrast 
microscopy.  Our results showed that EMD478761 induced morphological changes 
followed by the detachment of HUVECs from their substrate in a dose-dependent manner 
(Figure 4-7).  Cells treated with 0.6 µM of EMD478761 led to the detachment of all 
endothelial cells, while control cells remained well spread.  Since cell adhesion on ECM 
affects cytoskeletal dynamics (114), we examined the organization of the actin 
cytoskeleton of endothelial cells during the detachment process in the presence or 
absence of EMD478761. Immunostaining of HUVECs plated on vitronectin with Alexa® 
Fluro 568-conjugated phalloidin showed that EMD478761 induced rapid disruption of 
actin microfilaments in HUVECs followed by cell detachment from vitronectin-coated 
surfaces (Fig. 4-8 left panel).  Control cells displayed a well ordered array of transversal 









Figure 4-7.  Effect of EMD478761 on HUVECs spread on vitronectin (VN)-coated 
surfaces.  HUVECs were plated on vitronectin-coated 6-well plate.  Cells were grown 
until confluent before EMD478761 was added.  After 24 hours treatment, cells were 






Figure 4-8.  Effect of EMD478761 on actin filaments of HUVECs.  Red: phalloidin 
stained actin filaments; Blue: DAPI stained cell nuclei. Results from one out of six 




4.4.4  Effect of EMD478761 on Endothelial Cell Detachment on Fibronectin  
We tested the effect of EMD478761 on endothelial cells detachment on fibronectin, for 
which cell adhesion is largely mediated by α5β1 integrin (113).  HUVECs were plated on 
fibronectin-coated 6-well plates and 8-well chambers.  In contrast to the results obtained 
from cells attached to vitronectin surfaces, morphologic analyses showed that 
EMD478761 had no significant effect on HUVECs seeded on fibronectin (Fig. 4-9).   
Furthermore, no apparent actin filament changes were observed (Fig 4-8, right panel).  
HUVECs displayed a similar organized cytoskeleton on fibronectin with EMD478761 
treatment compared with control.  These results suggest that the action of EMD478761 is 
substrate specific and may relate to endothelial cell detachment. 
 
4.4.5  Effect of EMD478761 on Endothelial Cell Tube Formation 
The ability of HUVECs to form tubes was assessed on growth factor-reduced Matrigel 
containing increasing concentrations of EMD478761.  For this experiment, HUVECs 
were pre-incubated with different concentrations of EMD478761, as specified, for 30 min 
at 4 °C before being plated onto Matrigel overnight with EMD478761.  As shown in 
Figure 4-10, control cells formed an organized network of endothelial tubes.  In contrast, 
tube formation was reduced on Matrigel in the presence of 0.1 µM or higher 
EMD478761.  The inhibitory effect of EMD478761 at 1 µM was comparable to that 
exerted by C16Y, a known anti-angiogenic peptide that disrupted endothelial cell tube 





Figure 4-9.  Effect of EMD478761 on HUVECs spread on fibronectin (FN)-coated 









Figure 4-10.  Effect of EMD478761 on HUVEC tube formation. HUVECs were pre-
incubated with 0-1 µM EMD478761, as specified, for 30 min and plated onto Matrigel in 
the presence of different concentrations of EMD478761.  HUVECs were also treated 




4.4.6  Effect of EMD478761 on Apoptosis of Endothelial Cells in Vitro 
Activation of integrins αvβ3 and αvβ5 has been shown to enhance endothelial cell survival, 
and lack of substrate attachment has been shown to promote anoikis (a Greek 
word meaning “homelessness”) in endothelial cells (53, 116).  Therefore, we hypothesize 
that antagonists to integrins αvβ3 and αvβ5 will result in endothelia cell apoptosis.  To 
address the effect of EMD478761 treatment on HUVEC apoptosis, we first applied flow 
cytometry (FACS) analysis of Annexin V stained HUVECs in the presence of 
EMD478761 on different substrates.  As shown in Figure 4-11, EMD478761 promoted a 
dose-dependent induction of apoptosis in vitronectin-coated surfaces, as determined by 
Annexin V/ propidium iodide (PI) staining 24 hours after treatment.  The presence of 
early and late apoptotic cells in control conditions were around 21% and up to 51.4% of 
cells treated with a dose of 1 µM EMD478761 underwent apoptosis.  In contrast, FACS 
analysis revealed that EMD478761 did not facilitate HUVEC apoptosis on fibronectin 
surfaces (Fig. 4-12).  These results are consistent with those from cell detachment. 
 We further investigated the mechanisms by which EMD478761-induced 
apoptosis proceeded by examining the activation of caspases from HUVEC cell lysates 
prepared 12 to 24 hours after treatment by using Western blotting analysis.  As shown is 
Figure 4-13, treatment of cells with EMD478761 on vitronectin led to a time- and dose-
dependent activation of caspase-3, one of the key effector caspases, as determined by the 
appearance of the cleaved/active form of the enzyme and the decreased levels of the pro-
caspase 3.  Whereas, Western blotting revealed no evidence of caspase-3 activation for 





Figure 4-11.  FACS analysis of HUVEC apoptosis on vitronectin surfaces. HUVECs 
were treated with 0-1 µM EMD478761 for 41 hours and stained with Annexin V/PI.  The 





Figure 4-12.  FACS analysis of HUVEC apoptosis on fibronectin surfaces.  HUVECs 
were treated with 0-1 µM EMD478761 for 41 hours and stained with Annexin V/PI. The 




a downstream apoptotic enzyme, we then examined the upstream activations of caspases, 
in particular caspase-8 and caspase-9.  Interestingly, in our study, no caspase-8 activation 
was observed on cells plated on vitronectin- or fibronectin-coated surfaces, indicating 
that cell death did not occur by the activation of an extrinsic pathway.  Treatment of cells 
with EMD478761on vitronectin surfaces induced an increase in the cleaved form of 
caspase-9 (Fig. 4-14), suggesting that cell apoptosis involved caspase-9 activation. Again, 




Figure 4-13.  Effect of EMD478761 on the activation of caspase-3 on vitronectin surfaces.  
EMD478761 was added into the medium of endothelial cells plated on vitronectin after 
deprival of serum.  After 12 or 24 hours treatment, cells were lysed in RIPA buffer 
containing 1x complete proteinase inhibitors. Equal amount of total proteins were 
separated on 4-12% SDS-PAGE and detected with anti-caspase 3 antibody.  GAPDH 








Figure 4-14.  Effect of EMD478761 on endothelial cell activation of caspase-9.  
Endothelial cells plated on vitronectin or fibronectin were treated for 24 hours with 
EMD478761 at 0-1 µM, as specified.  Cells lysates were fractioned and blotted with anti-
caspase 9 antibody. GAPDH served as loading control.  The data are representative of 
three independent experiments. 
 
 
4.4.7  Effect of EMD478761 on Apoptosis of Vascular Endothelial Cells in Vivo  
In light of the induction of endothelial cells apoptosis in vitro, we next examined whether 
EMD478761 triggers vascular endothelial cell apoptosis in vivo using a laser-induced 
CNV rat model.  For these experiments, EMD478761 was given intravitreally 2 weeks 
after laser injury.  Treated eyes were collected 0, 5, 12 and 24 hours after injection.  
Flatmounts were generated and stained with isolectin IB4.  As shown in Figure 4-15, 
CNV areas with the treatment of EMD478761 appeared to be smaller than that of control 





Figure 4-15.  Effect of EMD478761 on laser-induced CNV regression in rats.  5 µg 
EMD478761 was delivered intravitreally to rat’s eyes 2 weeks after laser injury.  
Flatmounts were generated 0, 5, 12 and 24 hours after injection and stained with isolectin 
IB4 (green), DAPI (blue) or TUNEL (red). The images are representative of more than 30 




apoptosis occurred within CNV lesion.  These results were further confirmed by TUNEL-
stained retinal sections in which EMD478761 induced vascular endothelia cell apoptosis 
in the retina and within CNV (Fig. 4-16).  Twenty-four hours after treatment, TUNEL 
labeling showed that many apoptotic cells were observed within choroidal vascular beds, 
suggesting that EMD478761 regressed CNV by inducing endothelial cell apoptosis.  
Untreated controls demonstrated highly vascularized CNV and showed minimum 
TUNEL labeling within the retina overlying CNV.  The slightly positive TUNEL labeling 
of controls might be explained as a consequence of the laser photocoagulation or the 
presence of CNV that damaged the retina.  Our results are consistent with those 
previously described for antagonist of α5β1 integrin (26). 
 
4.5  Discussion 
Numerous studies have provided evidence that integrins αvβ3 and αvβ5 are highly 
expressed in angiogenic blood vessels in human granulation tissue, breast tumor 
vasculature as well as ocular neovascularization membrane(25, 58, 117).  Integrin 
molecules αvβ3 and αvβ5 can bind to ECM proteins through an Arg-Gly-Asp (RGD)–
binding site (113). Specific inhibitors, including blocking monoclonal antibodies, RGD 
peptide and RGD peptidomimetics have been developed and reported to inhibit tumor 
and ocular angiogenesis (57, 118, 119).  Some of these angiogenesis inhibitors, including 
a humanized monoclonal anti-αvβ3 (Vitaxin; MedImmune, Gaithersburg, MD) and an 
αvβ3/ αvβ5–selective RGD-based cyclic peptide (cilengitide), have entered clinical trials 





Figure 4-16.  Effect of EMD478761 on vascular endothelial cell apoptosis by TUNEL 
assay.  Red: apoptotic cells stained with TUNEL; green: vascular cells stained with 




antagonist to αvβ3 and αvβ5, inhibits angiogenesis in response to bFGF in the CAM and 
prevents laser-induced choroidal neovascularization in rats.  However, the drug’s action 
mode is unknown.  In this study, we have extended our previous work and investigated 
the antiangiogenic mechanisms of this compound.  We demonstrated that EMD478761 
inhibited HUVEC proliferation and tube formation, led to endothelial cell apoptosis both 
in vitro and in vivo.  Furthermore, we found that induction of angiogenesis inhibition or 
regression by this compound appeared to be closely correlated with its anti-attachment 
effect and involved with caspase-3 dependent endothelial cell apoptosis.  These results 
suggest a therapeutic role of EMD478761 in altering neovascularization in angiogenesis 
related disorders.  
The mechanisms by which EMD478761 abrogates angiogenesis are complex.  
Previous studies have shown that bFGF-induced angiogenesis is integrin αvβ3 dependent 
(57), and a monoclonal antibody directed against the αvβ3 integrin diminishes 
angiogenesis by inducing the apoptosis of angiogenic blood vessels (24).  Moreover, 
integrin αvβ3 provides a specific transmembrane signal that promotes angiogenic vascular 
cells survival in vivo, and antagonist to this integrin promotes the regression of human 
tumors (58).  The αvβ5 integrin has also been shown to participate in angiogenesis, and 
cyclic RGDfV peptide blocks angiogenesis by inhibiting αvβ5 integrin ligation (122).  We 
have shown in Chapter 2 that EMD478761 reverses angiogenesis by 80.6% in response to 
bFGF stimulation without affecting the normal CAM vasculature.  A similar effect was 
observed in the choroidal neovascularization animal model where αvβ3 integrin is over 
expressed on endothelial cells of CNV membrane (25), and treatment with EMD478761, 




However, the extent of regression of CNV was much smaller than that of CAM.  This 
probably reflects the inadequate dose injected or the fast clearance of this compound 
from the vitreous.  Alternatively, the integrin αvβ3 turnover time is so short that the elapse 
of EMD478761 can provide the opportunity for integrin signaling.  In addition, it is likely 
that the attenuation of the proliferative response of endothelial cells may be mediated by 
αv-integrin since angiogenesis starts well before the treatment.  
 Previous studies indicates that cell adhesion to ECM regulates the life cycle of 
integrins and it is important for cellular signaling transduction (123).  In our experiments, 
EMD478761 prevented endothelia cell adhesion to vitronectin within one hour treatment.  
Moreover, the induction of angiogenesis regression by EMD478761 was also found to 
closely correlate with its anti-proliferation and anti-tube formation effects and its ability 
to detach endothelial cells from specific substrates.  The effects that EMD478761 showed 
on BrdU incorporation, PCNA and p21 expression indicated its strong anti-proliferative 
action on endothelial cells.  Cell adhesion to vitronectin is mainly αvβ3 and αvβ5  
integrins mediated (113).  As expected, EMD478761 led to significant endothelial cell 
detachment on this substrate.  As a result, the actin filaments were also rapidly disrupted 
in a dose-dependent manner, which in turn may have led to the activation of endothelial 
cell apoptosis.  In contrast, HUVECs attached to fibronectin-coated surfaces did not show 
any morphological changes or actin filament depolymerization.  The disruption of 
endothelial cell tube formation on Matrigel by EMD478761 may be attributed partially to 
the alteration of an integrin signaling pathway, which could be related to cytoskeletal 
filaments, such as actin. 




types (93, 113).  Apoptosis is controlled by multiple signaling and effector pathways that 
mediate active responses to external growth, survival or death factors.  A hallmark of cell 
apoptosis is the activation of nucleases that degrade the higher order chromatin structure 
of the DNA into fragments of 50 to 300 kilobases and subsequently into smaller DNA 
pieces of about 200 base pairs in length (124, 125).  These new DNA ends that are 
generated upon DNA fragmentation are typically localized in morphologically 
identifiable nuclei and apoptotic bodies and can be detected by enzymatically labeling the 
free 3’-OH termini with modified nucleotides.  TUNEL labeling assay indicated that 
apoptosis occurred within CNV lesions as early as 5 hours after intravitreal injection of 
EMD478761.  
 The next possible mechanism that we investigated is that EMD478761 induced 
endothelial cell apoptosis through caspase-dependent pathways.  Caspases, the principal 
biochemical effectors of apoptosis, are present in cells as inactive zymogens (pro-
caspases).  Once activated, upstream apoptotic signals convert these precursors into 
mature proteases that cleave their substrates after aspartate residues (113).  Two principal 
caspase-dependent pathways that mediate apoptosis in endothelial cells are: the intrinsic 
apoptosis pathway triggered in response to mitochondrial changes, leading to caspase-9 
activation, and the extrinsic pathway initiated by surface receptor mediated caspase-8 
activation (126).  Activation of caspase-8 and caspase-9 pathways have been described in 
different cell types after integrin antagonism or disruption of adhesion (127-129).  Both 
pathways result in the down stream activation of executioner caspases, such as caspase-3.  
In this study, we found the activation of caspase-3 in response to EMD478761 treatment.  




death in HUVECs resulted from activation of the Fas and caspase-8 pathway (113, 127).  
Interestingly, in our experimental conditions, no caspase-8 activation was detected; while 
the cleavage of caspase-9 was observed.  This suggests that the intrinsic pathway appears 
to dominate over the extrinsic pathway in endothelial cell apoptosis on a vitronectin 
surface.  In contrast, EMD478761 did not exert any apoptotic effect on HUVECs plated 
on fibronectin surfaces as we did not observe any cleavage of caspases.  Therefore, 
EMD478761 did not promote integrin-mediated cell death, a model where unligated or 
antagonized integrins directly recruit caspase-8 and trigger the apoptosis of adherent cells.  
Apparently, further investigations will warrant a better understanding of the 
antiangiogenic action mode of this compound, and guide the optimization of therapeutic 
interventions. 
 
4.6  Conclusions 
In summary, we provided several lines of evidence that EMD478761 might offer an 
effective treatment for angiogenesis associated diseases.  We demonstrated that 
EMD478761 prevented human endothelial cell proliferation and tube formation, as well 
as induced endothelial cell detachment and triggers endothelial cell apoptosis on 
vitronectin.  In vitro, EMD478761 induced cell cycle arrest as indicated by reduced BrdU 
incorporation, decreased proliferating nuclear antigen (PCNA) expression and an 
increased p21 protein levels in the nuclei.  EMD478761 also prevented HUVEC 
adhesion, caused endothelial cell detachment from vitronectin, as well as activated the 




EMD478761 induce endothelial cell death in vascular cells within the neovascularization 
lesions in laser-induced CNV as determined by TUNEL staining. These results suggest 






Chapter 5:  Integrin Regulation by EMD478761 
 
 
5.1  Introduction 
The interaction of cells with the extracellular matrix is mediated by integrins.  
Endothelial cells express many structurally distinct integrins including αvβ3, αvβ5 and α5β1 
(130).  Each α β integrin combination has specific binding and signaling properties.  In 
general, cell-substratum adhesion occurs at sites of the plasma membrane called focal 
contacts or adhesion plaques, where integrins and cytoskeletal proteins are concentrated 
(131).  Adherent cells anchor via integrins to the matrix is essential to maintain the 
survival of the cells.  Therefore, it has been suggested that cell attachment through 
various integrins, including αvβ3 and α5β1, can prevent apoptosis of endothelial cells (132, 
133).  In addition to this structural role, integrin signaling is of vital importance to many 
physiological events, such as cell differentiation, migration and tube formation (134).  
Two types of integrin signaling exist: “outside-in” signals that originate from the matrix 
to the inside of the cell, promoting a variety of cellular responses, and “inside-out” 
signals that start at the cytoplasm and affect the adhesive properties of integrins to their 
matrix.  It is clear that dysfunction in these processes can lead to diseases such as cancer 
(134).  The cellular mechanisms regulating integrin function are currently the subject of 
considerable focus for cell biologists.  One possible mechanism is integrin receptor 
endocytosis.  The focus of this chapter is to study the effect of EMD478761 on integrin 




 Integrin endocytosis has been shown to be connected to several phenomena, 
including cell migration, reorganization of extracellular matrix components and uptake of 
fibrinogen from plasma (135, 136).  It is clear that certain integrin heterodimers are 
continually internalized from the plasma membrane into endosomal compartments and 
then recycled back to the cell surface, completing an endo-exocytic cycle (104).  The 
integrin cycling time ranges from 10 min to 30 min depending on which of two loops the 
integrin recycling takes.  The short loop refers to the route that integrin recycles from 
early endosomal compartment (EE) to the plasma membrane.  The half-life of transport 
of αvβ3 via short-loop is approximately 3 to 5 min.  However, the delivery of integrins 
αvβ3 and α5β1 from the perinuclear recycling compartment (PNRC) to the plasma 
membrane, often refers as long-loop, has a t ½ of approximately 10 min (134).  There is 
abundant evidence indicating that integrin traffic is Rab GTPase-and kinase-dependent 
(104, 137).  A schematic summary of integrin turnover is shown in Figure 5-1. 
Several studies have been performed to elucidate the process of integrin 
internalization and recycling.  Among those, integrins αvβ3 and α5β1 are mostly studied in 
fibroblast 3T3 cells (104), platelets (138), or calf lung endothelial cells (139).  In order to 
track the internalized integrins and differentiate them from others, specific cell surface 
integrins are often labeled at 4°C with fluorescein-conjugated antibodies or tagged with 
membrane non-permeable biotin.  At this temperature, membrane proteins can not be 
internalized.  Labeled cells are then allowed to internalize by raising the temperature to 
37°C.  Surface remaining fluorescence, corresponding to non-internalized proteins, can 
be removed by acidic buffer wash (139) or blocked with anti-fluorescein antibodies 




quantified by flow cytometry (139).  Biotin tags are often quenched by 2-
mercaptoethanesulfonate (MesNa) reduction (104).  Internalized integrins are 




Figure 5-1.  Schematic draw of integrin trafficking via short-loop (dash arrow) and long-
loop (solid arrow) (Adapted from (134)).  EE: early endosomal compartment; PNRC: 








5.2  Materials and Methods 
 
5.2.1  Compound and Endothelial Cell Culture 
EMD 48761 was obtained from Merck KGaA (Darmstadt, Germany).  It was solubilized 
to a concentration of 0.5 mg/ml in phosphate buffered saline (PBS).  HUVECs were 
maintained in complete RPMI 1640 medium containing growth factors as described in 
Chapter 4. 
 
5.2.2  Quantitation of Integrin Cell Surface Expression by Flow Cytometry  
Cell surface αvβ3 integrins were measured by flow cytometry.  For these experiments, 
sub-confluent HUVECs grown in 6-well plate were serum starved with human 
endothelial cell serum free medium (SFM) for 30 min and then cells were treated with 
EMD478761 at indicated concentrations (0-1µM) for 12 or 24 hours.  After treatment, 
HUVECs were washed three times with PBS devoid of calcium and magnesium and 
detached from the culture dishes by incubating for 10 minute at 4°C in Versene (0.48 
mM EDTA, Invitrogen).  Cell surface integrins were labeled in suspension using Alexa 
Fluro 488-conjugated monoclonal antibodies to αvβ3 integrin (Chemicon) under non-
permeabilizing conditions.  The fluorescence intensity of the Alexa-488 fluorescein dye 
is insensitive to pH changes, which allows for the antibodies to be stripped off with low 
pH glycine buffer without affecting the fluorescence intensity of internalized antibodies 






5.2.3  Immunofluorescence and FACS Analysis of Integrin Internalization 
To study integrin internalization, cultured HUVECs were treated with EMD478761.  
Cells were labeled with primary Alexa®488-conjugated antibodies against αvβ3 integrins 
(Chemicon) at 4°C for 1hour to prevent integrin internalization.  After allowing 
endocytosis to proceed at 37°C for various time intervals (5, 10, 15, 20 or 30 minutes), 
we then detached the cells with Versene.  To detect only those internalized fluorophore-
labeled integrins, residual surface-bound antibodies were removed by washing the cells 
twice (2 minutes/wash) with an acidic antibody-stripping buffer (50 mM glycine, 150 
mM NaCl, pH 2.5) at 4°C.  The antibody-stripping buffer has been previously 
demonstrated to be able to remove cell surface bound antibodies effectively (139).  After 
stripping, the labeled cells were either spin-coated onto a slide for immunofluorescence 
microscopic examination or subjected to flow cytometry analysis.   
 
5.2.4  Quantitative analysis of integrin internalization by biotin labeling 
Integrin internalization was also studied using a modified biotin-labeling technique (104).  
A membrane non-permeable biotin was used to label cell-surface membrane proteins and 
to determine integrin molecules that are internalized.  The schematic representation of 






Figure 5-1.  Schematic representation of integrin internalization with biotin labeling.. 
HUVECs were extensively washed with ice cold PBS before labeling with 1 mg/ml 
NHS-SS-biotin.  Labeled cells were incubated at 37 °C for indicated time to allow 
internalization to proceed.  Surface biotin was removed and internalized integrins were 




Subconfluent HUVECs were serum starved for 30 minutes and washed 5 times 
with ice-cold PBS to remove serum-derived proteins.  Cell surface proteins (including 
integrins and other receptors) were biotinylated with Sulfo-NHS-SS-Biotin (Pierce;  
Fig. 5-3) at 1 mg/ml for 15 min at 4°C.  Cells were then returned to 37°C in serum free 
medium in the presence or absence of 0.6 µM EMD478761 for 0, 5, 10, 20 and 30 min to 
allow internalization of labeled surface proteins to proceed.  Cells were transferred to ice 
after the medium was aspirated.  Biotin was removed from those non-internalized or 
recycled labeled proteins by incubation with a solution containing 20 mM sodium 2-
mercaptoethanesulfonate (MesNa, a membrane-impermeant reducing agent; Sigma) in 50 
mM Tris, pH 8.5, and 100 mM NaCl for 15 minutes at 4°C.  After surface reduction, cells 
were washed twice with ice-cold PBS.  MesNa was quenched by the addition of 20 mM 
iodoacetamine (IAA; Sigma) for 10 minutes and then the cells were lysed in RIPA buffer 
(Pierce) containing proteinase inhibitors.  The protein levels were determined using the 
BCA protein assay kit (Pierce).  Cell lysate with equal amounts of total protein was pre-
cleared by incubation with protein-G beads (Millipore, Billerica MA) alone and then was 
immunoprecipitated with antibody αvβ3 pre-treated protein G beads.  The bead-bound 
proteins were solubilized in boiled 1x SDS-gel sample buffer (Invitrogen) under non-
reducing conditions and clarified by centrifugation.  Immunoprecipitated integrins were 
separated with 4-12% SDS-PAGE under non-reducing conditions.  Biotinylated proteins 
were detected with streptavidin-conjugated horseradish peroxidase (HRP) and visualized 







Figure  5-3.  Labeling reaction of biotin with surface proteins. 
 
 
5.3  Results  
 
5.3.1  Effect of EMD478761 on Integrin αvβ3 Expression 
In light of the inhibition effects of sustained delivery of EMD478761 on several in vivo 
angiogenesis assays and the involvement of integrin αvβ3 in angiogenic vessels, we first 
evaluated the integrin αvβ3 expression levels on endothelial cells in the presence of 
EMD478761.  As shown in Figure 5-4, the flow cytometry analysis indicated that surface 
integrin αvβ3 expression levels were not significantly changed in either control or 
EMD478761 treated cells over the 12 hours interval.  However, we observed a pronounce 
decrease in cell-surface integrin αvβ3 expression levels followed by cell detachment after 






Figure 5-4.  Effect of EMD478761 on endothelial cell surface integrin αvβ3 expression. 
HUVECs were labeled with Alexa 488-conjugated anti- αvβ3 antibodies 12 and 24 hours 
after EMD478761 treatment (concentration range: 0-0.6 µM).  Labeled cells were 




5.3.2  Effect of EMD478761 on Integrin αvβ3 Internalization 
We next examined whether EMD478761 can affect αvβ3 integrin internalization from the 
endothelial cell surface.  For these experiments, the surface integrin of αvβ3 of HUVECs 




incubated either at 37°C in the presence or absence of 0.6 µM EMD478761 to allow 
integrin internalization to occur or at 4 °C as non-internalization control.  The residual 
surface integrin-bound antibody was removed by an acidic glycine buffer washing.  The 
cells were then fixed for flow cytometry analysis, or permeabilized for fluorescence 
microscopy examination.  Our results showed a significant increase in fluorescence 
intensity of EMD478761-treated endothelial cells as compared to controls (Fig. 5-5), 
suggesting that EMD478761 affected integrin αvβ3 internalization. To confirm these 
observations from flow cytometry studies, cell suspensions were also subjected to 
fluorescence microscope visualization.  As shown in Figure 5-5 insert, fluorescence 
microscopy of HUVECs revealed that for both control cells and EMD478761 treated 
cells, integrin internalization was elevated with the increasing of internalization time.  
However, the addition of EMD478761 markedly increased the internalization of the αvβ3 
integrin as compared to control cells.  
Internalization of αvβ3 integrin was detected by fluorescence microscope as early 
as 5 minutes after the process was allowed to proceed at 37°C, suggesting a rapid 
endocytosis of these surface integrins taken place in control cells and EMD478761 
treated cells. Moreover, the level of increase in integrin αvβ3 internalization appeared to 
be more with the fluorescence microscope visualization than that of flow cytometry 
analysis.  This might be due to the effect of the clustering and aggregation of antibody-
tagged integrin αvβ3, which greatly enhanced the visualization of internalized integrins by 







Figure 5-5.  Flow cytometry analysis of integrin αvβ3 internalization in endothelial cells in 
the presence of 0.6 µM EMD478761.  Subconfluent HUVECs were labeled with Alexa 
488-conjugated anti- αvβ3 antibodies at 4°C.  After incubated at 37°C for indicated time 
intervals, surface-bound antibodies were removed by the antibody stripping buffer.  Cells 
were then subjected to flow cytometry analysis or fluorescence microscope visualization.  
Insert: fluorescence images of integrin αvβ3 internalization in the presence of 0.6 µM 
EMD478761. Bar represents mean ± S.D. of 3 independent experiments. (P < 0.05 as 





Integrin αvβ3 internalization was further investigated by a biotin-labeling assay.  
Integrin αvβ3 internalization was determined by surface labeling HUVECs with Sulfo-
NHS-SS-biotin at 4°C, followed by incubation at 37°C for various time intervals. 
Internalized integrins were assessed by immunoprecipitation, followed by Western 
blotting with streptavidin.  The integrin αvβ3 internal pool reached a steady level by 
around 10 min for EMD478761 treated cells and 15 min for controls (Fig. 5-6).  We also 
observed that the addition of EMD478761 increased the measured integrin αvβ3 
internalization.  These results were consistent with those of flow cytometry analysis and 




Figure 5-6.  Effect of EMD478761 on integrin αvβ3 internalization by biotin labeling. 
HUVECs were labeled with biotin at 4°C and then they were incubated at 37°C for 
different time intervals, as specified.  Surface remaining biotin was removed by MesNa 
reduction.  Internalized integrin αvβ3 was immunoprecipitated and fractioned by SDS-






5.4  Discussion 
Recycling of cell-surface integrins is a constitutive process in adherent cells and is 
believed to play a vital role in cell adhesion, remodeling of the ECM, and the migration 
of adherent cells (141, 142).  Like other recycling events related to a variety of cell-
surface receptors, the initial step of integrin recycling is integrin receptor internalization, 
a process believed to occur by endocytosis (141, 143).  In the present study, we examined 
the effect of EMD478761 on the expression and internalization of the surface integrin 
αvβ3 in HUVECs using fluorescein and biotin labeling methods.   
Our preliminary results showed that total cell-surface integrin αvβ3 expression in 
HUVECs was not affected by the presence of EMD478761 after 12 hours.  Moreover, we 
observed that EMD478761 increased integrin αvβ3 internalization, which was supported 
by fluorescence microscopy and flow cytometry analysis, and it was further confirmed by 
Western blotting analysis.  A possible explanation for this observation could be due to 
increased degradation of the endocytosed integrin αvβ3 after EMD478761 exposure, and 
that this degradation was compensated by increased synthesis and secretion of new 
integrin αvβ3, which maintained the surface levels of integrin αvβ3 despite increased of 
integrin internalization.  However, this possibility appears to be unlikely since the 
observation of elevated integrin internalization was within short period of time.  
Increasing evidence showed that the half-life of integrin turnover in adherent cells 
(fibroblast and endothelial cells) is about 8-10 hours (144), while recycling of such 
integrins has been documented to proceed much rapidly with a half-life of about 5-10 




consequence of elevated integrin recycling rate rather than integrin synthesis and 
degradation. 
Although the physiologic/pathologic significance of integrin recycling is not 
clearly understood, recycling of αvβ3 and other integrins has been suggested to mediate 
cell migration, spreading (141, 145), and modulate surface-bound ligand (138).  The life 
cycle of integrin involves constitutive synthesis, recycling and degradation.  Integrin 
binging to ECM was believed to prevent the degradation and internalization.  Once the 
cells lost their contact with ECM, adhesion-dependent signals initiated by the binding of 
ECM to cell surface integrins was blocked.  As a result, cell shape and cytoskeletal 
organization were changed.  Therefore, the biological consequence of integrin αvβ3 
internalization as seen in this experiment might be explained as a potential mechanism 
for limiting the extent of adhesion-dependent signaling. 
Previous studies demonstrated that integrin αvβ3 recycling through long-loop or 
short-loop was Rab-dependent, and was regulated by platelet derived growth factor 
(PDGF) (104).  In this investigation, we only observed that there is an increase in integrin 
αvβ3 internalization in the presence of EMD478761.  The biological consequence of such 
enhanced integrin internalization may contribute to endothelial cell detachment and 
angiogenesis inhibition. Further studies will warrant a better understanding of the effect 






5.5  Conclusions 
In this study, we have demonstrated that endothelial cell surface integrin αvβ3 expression 
levels were not affected by the presence of EMD478761 for up to 12 hours.   




Chapter 6:  Summary and Perspectives 
 
 
6.1  Summary 
 
In summary, this study was initiated to target choroidal neovascularization by 
antagonizing a specific angiogenesis marker using a sustained delivery system.  It was 
motivated by the facts that integrins αvβ3 and αvβ5 are up-regulated in the ocular 
angiogenic vessels while undetectable in mature/quiescent blood vessels, and anti-
integrin compounds appear to potently block cytokine and tumor-induced angiogenesis in 
several animal models.  In addition, continuous delivery of other anti-angiogenic 
compounds, such as endostatin, increases the efficacy and potency of anti-tumor 
therapies.  We integrated a system that took advantages of the novel integrin antagonist, 
EMD478761, and a sustained delivery device, which can potentially deliver the drug at 
controlled release rates to the site of neovascularization, while bypassing the major ocular 
drug delivery barriers.   
 PVA reservoir type implants were designed to release the drug for a desired 
period of time.  The parameters, which influence the release rates of the implants 
including PVA concentrations, implant sizes and curing temperature, were evaluated.  
The release rates of the implants decreased as the PVA concentrations and the curing 
temperatures increased, while they increased proportionally to the sizes of the implant.  A 




specifically for the laser-induced CNV rat model.  Both types of implants delivered an 
initial burst of drug on the first day, followed by a constant release for an extended period 
of time, which then gradually decreased.  The steady-state release kinetics followed a 
zero order, which is typical for diffusion controlled drug release devices.   
 Initial experiments were performed to investigate the angiogenic inhibitory 
efficacy of the EMD478761 implant using a modified CAM assay (Chapter 2).  Results 
showed that sustained delivery of EMD478761 pronouncedly inhibited bFGF-induced 
angiogenesis in the CAM assay.  In average, 85% and 90% of the control CAMs were 
positive in the presence of bFGF and bFGF with sham implant, respectively.  However, 
only 19% of the bFGF-induced CAMs were weakly angiogenic in the presence of the 
EMD478761 implant.  In terms of neovascularization area, bFGF alone induced an 
average of 6.8 ± 5.3 mm2, and bFGF with sham implant induced a similar area of 6.3 ± 
3.1 mm2.  In contrast, the presence of the EMD478761 implant dramatically decreased 
the neovascularization area to only 0.47 ± 1.2 mm2.  We further examined the ability of 
this implant to regress existing neovascularization in the CAM by adding the implant 
three days after the angiogenesis was induced.  Interestingly, EMD478761 significantly 
decreased the neovascularization area by 80% after 2 days of treatment without affecting 
the normal CAM vasculature.  These results were highly encouraging and they suggested 
that our sustained delivery system could be useful for the management of angiogenesis-
related diseases. 
 A more in-depth anti-angiogenesis study was performed on a CNV animal model 
induced by a diode laser (Chapter 3).  We compared the efficacy of intravitreal bolus 




microimplant significantly suppressed laser-induced CNV in rats by 63% to 65% 2 weeks 
after implantation.  However, intravitreal injection of EMD478761 failed to abrogate the 
development of CNV.  Histopathological studies corroborated the above findings.  These 
results suggested that single intravitreous injection might not be able to deliver or 
maintain sufficient levels of EMD478761 to significantly inhibit CNV; therefore a 
sustained delivery device is necessary. 
 Once the anti-angiogenic properties of these implants were proved, we next 
examined EMD478761’s action mode (Chapters 4 and 5).  Endothelial cells are key 
player in the angiogenesis cascade as they form the lumen of every blood vessel.  We 
found than EMD478761 inhibited endothelial cell proliferation, tube formation, and 
mediated endothelial cell apoptosis in a time- and dose- dependent manner.  We also 
observed that EMD478761 induced apoptosis was substratum-dependent and involved 
caspase-3 activation.  EMD478761 caused rapid disruption of actin microfilaments in 
HUVECs grown on vitronectin-coated surfaces followed by cell detachment in a dose-
dependent manner, while there was no such effect was observed with cells plated on 
fibronectin-coated surfaces.  These findings indicated that the action of EMD478761 is 
αv-specific and may be mediated by inducing cell detachment. 
 Finally, we investigated the effect of EMD478761 on integrin receptor regulation, 
in particular, on integrin αvβ3 expression and internalization.  Our preliminary results 
demonstrated that EMD478761 increased the integrin αvβ3 internalization in endothelial 
cells, while total surface integrin αvβ3 was not affected.  This result suggests that 




consequence of integrin internalization and its relationship with anti-angiogenesis 
abilities need to further investigated. 
 
6.2  Perspectives 
In this study, we demonstrated the anti-angiogenic potency of sustained delivery of 
EMD478761.  However, AMD is a chronic disease, which may need months to years 
treatment, it will be worthwhile to design a new implant with longer release period 
(years) for future preclinical and clinical studies.  A preliminary approach has been taken 
to design a composite silicone reservoir implant that can release EMD478761 at a 
constant rate for up to a year (Fig.6-1).  
Pharmacokinetic studies will be needed to predict the drug distribution and 
elimination after implantation.  In this study, we used rat to assess the in vivo efficacy of 
EMD478761, however, the vitreous volume of the rat eye is too small to perform direct 
pharmacokinetics studies.  Moreover, the solubility of this drug in normal physiological 
saline is limited, conventional drug extraction methods with certain organic solvents such 
as acetonenitrile and methanol, are not ideal, especially when drug concentrations are 
extremely low.  In order to obtain the experimental data, it will be better to use larger 
animals such rabbits.  Additionally, it will also be interesting to conjugate fluorescein or 
contrast agents to this drug, therefore allowing direct in vivo tracking of drug 
distribution.  Finally, it will be useful to build a mathematical model to provide a better 
understanding of drug movement and predict drug levels inside the eye, and offer 





Figure 6-1.  A long-term release EMD478761 implant (A, B) and its in vitro release 





In this study, we observed that EMD478761 facilitated integrin αvβ3 
internalization.  However, we were not clear about its biological consequences. Future 
studies will warrant a better understanding regarding the connection of integrin 
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